

Characterization of the receptor-binding domain (RBD) implication for development of RBD protein as a viral a

Cellular and Molecular Immunology

17, 613-620

DOI: [10.1038/s41423-020-0400-4](https://doi.org/10.1038/s41423-020-0400-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting acute kidney injury in COVID-19. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1652-1662.	0.4	58
2	The COVID-19 pandemic: a global health crisis. <i>Physiological Genomics</i> , 2020, 52, 549-557.	1.0	281
3	The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 595739.	2.2	90
4	Functionalized TiO ₂ Nanotube-Based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2. <i>Sensors</i> , 2020, 20, 5871.	2.1	147
5	A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets?. <i>Drug Discovery Today</i> , 2020, 25, 2317-2325.	3.2	12
6	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. <i>International Immunopharmacology</i> , 2020, 89, 107082.	1.7	23
7	Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2. <i>Toxicology Reports</i> , 2020, 7, 1366-1372.	1.6	9
8	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. <i>British Journal of Biomedical Science</i> , 2020, 77, 168-184.	1.2	12
9	Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes: Moving Toward a Universal Vaccine for the "Confined Virus". <i>Pathogens</i> , 2020, 9, 829.	1.2	51
10	Research Progress of Genetic Structure, Pathogenic Mechanism, Clinical Characteristics, and Potential Treatments of Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 1327.	1.6	4
11	COVID-19 Vaccine: A comprehensive status report. <i>Virus Research</i> , 2020, 288, 198114.	1.1	628
12	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. <i>Nature Protocols</i> , 2020, 15, 3699-3715.	5.5	291
13	Druggable targets from coronaviruses for designing new antiviral drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115745.	1.4	20
14	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. <i>Genes and Diseases</i> , 2021, 8, 385-400.	1.5	60
15	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. <i>Viruses</i> , 2020, 12, 1104.	1.5	29
16	Molecular Diagnosis of Coronavirus Disease 2019. , 2020, 2, e0184.		6
17	In-silico design of a potential inhibitor of SARS-CoV-2 S protein. <i>PLoS ONE</i> , 2020, 15, e0240004.	1.1	36
18	Potential Therapeutic Options for COVID-19. <i>Infectious Microbes & Diseases</i> , 2020, 2, 89-95.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19. <i>Journal of Chemical Neuroanatomy</i> , 2020, 110, 101874.	1.0	16
20	Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1970-1978.	2.0	30
21	Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. <i>Scientific Reports</i> , 2020, 10, 17699.	1.6	173
22	Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106192.	1.1	18
23	Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. <i>Science Advances</i> , 2020, 6, .	4.7	57
24	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. <i>Lancet, The</i> , 2020, 396, 1595-1606.	6.3	511
25	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. <i>Microorganisms</i> , 2020, 8, 1468.	1.6	9
26	Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19?. <i>Environmental Research</i> , 2020, 191, 110053.	3.7	48
27	Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>Indian Pacing and Electrophysiology Journal</i> , 2020, 20, 193-198.	0.3	40
28	New insights on possible vaccine development against SARS-CoV-2. <i>Life Sciences</i> , 2020, 260, 118421.	2.0	8
29	Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. <i>Vaccine</i> , 2020, 38, 7205-7212.	1.7	31
30	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. <i>Virus Research</i> , 2020, 288, 198141.	1.1	116
31	Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. <i>Journal of Proteome Research</i> , 2020, 19, 4587-4608.	1.8	72
32	Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. <i>Emerging Microbes and Infections</i> , 2020, 9, 2269-2277.	3.0	29
33	Cyanobacterial metabolites as promising drug leads against the M ^{pro} and PL ^{pro} of SARS-CoV-2: an <i>in silico</i> analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6218-6230.	2.0	35
34	Immune-mediated approaches against COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 630-645.	15.6	260
35	Neurological manifestations of COVID-19: a systematic review. <i>Critical Care</i> , 2020, 24, 421.	2.5	141
36	Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. <i>Frontiers in Immunology</i> , 2020, 11, 1472.	2.2	38

#	ARTICLE	IF	CITATIONS
37	Diabetes and Novel Coronavirus Infection: Implications for Treatment. <i>Diabetes Therapy</i> , 2020, 11, 1915-1924.	1.2	6
38	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 367-375.	1.8	24
39	Immunoglobulin fragment F(ab ²) against RBD potently neutralizes SARS-CoV-2 in vitro. <i>Antiviral Research</i> , 2020, 182, 104868.	1.9	48
40	Current and Perspective Diagnostic Techniques for COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 1998-2016.	1.8	116
41	Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. <i>Future Medicinal Chemistry</i> , 2020, 12, 1647-1656.	1.1	49
42	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00623.	1.1	13
43	In Search of Herbal Anti-SARS-Cov2 Compounds. <i>Frontiers in Plant Science</i> , 2020, 11, 589998.	1.7	18
44	Computational Design of 25-mer Peptide Binders of SARS-CoV-2. <i>Journal of Physical Chemistry B</i> , 2020, 124, 10930-10942.	1.2	37
45	Detection, Mapping, and Proteotyping of SARS-CoV-2 Coronavirus with High Resolution Mass Spectrometry. <i>ACS Infectious Diseases</i> , 2020, 6, 3269-3276.	1.8	34
46	Amino acid interacting network in the receptor-binding domain of SARS-CoV-2 spike protein. <i>RSC Advances</i> , 2020, 10, 39831-39841.	1.7	18
47	Recombinant vaccines for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2905-2912.	1.4	64
48	Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps. <i>Current Diabetes Reports</i> , 2020, 20, 77.	1.7	14
49	Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-12.	2.0	12
50	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	79
51	<p>Silver-Based Nanomaterials as Therapeutic Agents Against Coronaviruses: A Review</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 9301-9315.	3.3	37
52	Investigation of the Effect of Temperature on the Structure of SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 583523.	1.6	55
53	Molecular Dynamics Reveals Complex Compensatory Effects of Ionic Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 Spike/Human Angiotensin-Converting Enzyme 2 Interaction. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 10446-10453.	2.1	20
54	Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. <i>Vaccines</i> , 2020, 8, 654.	2.1	32

#	ARTICLE	IF	CITATIONS
55	Development of Diagnostic Tests for Detection of SARS-CoV-2. <i>Diagnostics</i> , 2020, 10, 905.	1.3	32
56	Intra- and intermolecular atomic-scale interactions in the receptor binding domain of SARS-CoV-2 spike protein: implication for ACE2 receptor binding. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 18272-18283.	1.3	53
57	Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 7231-7245.	2.0	56
58	Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 1748.	2.2	169
59	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. <i>EBioMedicine</i> , 2020, 58, 102907.	2.7	110
60	Low Incidence and Mortality from SARS-CoV-2 in Southern Europe. Proposal of a hypothesis for Arthropod borne Herd immunity. <i>Medical Hypotheses</i> , 2020, 143, 110121.	0.8	2
61	Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1033-1046.	1.4	70
62	A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1874-1878.	0.9	29
63	Phosphate Derivatives of 3-Carboxyacylbetulin: Synthesis, In Vitro Anti-HIV and Molecular Docking Study. <i>Biomolecules</i> , 2020, 10, 1148.	1.8	14
64	Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. <i>Frontiers in Immunology</i> , 2020, 11, 2008.	2.2	23
65	Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 100, 107697.	1.3	52
66	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. <i>Pharmaceuticals</i> , 2020, 13, 155.	1.7	88
67	COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella. <i>Frontiers in Immunology</i> , 2020, 11, 1714.	2.2	25
68	A Thermostable mRNA Vaccine against COVID-19. <i>Cell</i> , 2020, 182, 1271-1283.e16.	13.5	485
69	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. <i>Journal of Drug Targeting</i> , 2020, 28, 683-699.	2.1	26
70	Deciphering the TCR Repertoire to Solve the COVID-19 Mystery. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 518-530.	4.0	57
71	Drug Discovery Strategies for SARS-CoV-2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 127-138.	1.3	83
72	Clinical Characteristics and Eosinophils in Young SARS-CoV-2-Positive Chinese Travelers Returning to Shanghai. <i>Frontiers in Public Health</i> , 2020, 8, 368.	1.3	9

#	ARTICLE	IF	CITATIONS
73	Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. <i>Science</i> , 2020, 369, 1603-1607.	6.0	678
74	Developing a low-cost and accessible COVID-19 vaccine for global health. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008548.	1.3	66
75	Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110559.	2.5	64
76	New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?. <i>Cellular Immunology</i> , 2020, 356, 104187.	1.4	22
77	Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5338.	1.8	37
78	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. <i>Life Sciences</i> , 2020, 258, 118166.	2.0	79
79	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. <i>Cell Research</i> , 2020, 30, 932-935.	5.7	124
80	Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia. <i>Science Advances</i> , 2020, 6, .	4.7	19
81	Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Journal of the Chinese Medical Association</i> , 2020, 83, 725-732.	0.6	27
82	Endo-Lysosomal Cation Channels and Infectious Diseases. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, , 259-276.	0.9	19
83	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 588618.	1.6	77
84	COVID-19 update: The race to therapeutic development. <i>Drug Resistance Updates</i> , 2020, 53, 100733.	6.5	49
85	Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age. <i>Frontiers in Physiology</i> , 2020, 11, 590787.	1.3	37
86	SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination. <i>Advanced Materials</i> , 2020, 32, e2005637.	11.1	74
87	A graph-based approach identifies dynamic H-bond communication networks in spike protein S of SARS-CoV-2. <i>Journal of Structural Biology</i> , 2020, 212, 107617.	1.3	26
88	Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations. <i>Journal of Physical Chemistry B</i> , 2020, 124, 10034-10047.	1.2	54
89	Targeting Crucial Host Factors of SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2020, 6, 2844-2865.	1.8	28
90	The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. <i>Cells</i> , 2020, 9, 2343.	1.8	73

#	ARTICLE	IF	CITATIONS
91	How ADA methodology informs SARS-CoV-2 assay development. <i>Bioanalysis</i> , 2020, 12, 1275-1277.	0.6	0
92	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. <i>Journal of Proteome Research</i> , 2020, 19, 4291-4315.	1.8	68
93	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. <i>Frontiers in Immunology</i> , 2020, 11, 576622.	2.2	317
94	CoVaccine HT [®] , [®] Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. <i>Frontiers in Immunology</i> , 2020, 11, 599587.	2.2	27
95	Designing a multi-epitope peptide based vaccine against SARS-CoV-2. <i>Scientific Reports</i> , 2020, 10, 16219.	1.6	87
96	Phase 1 [®] Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2320-2332.	13.9	1,000
97	SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	57
98	The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. <i>Frontiers in Immunology</i> , 2020, 11, 1880.	2.2	60
99	Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight. <i>PLoS ONE</i> , 2020, 15, e0238344.	1.1	76
100	Case series and review of liver dysfunction in COVID-19 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1244-1250.	0.8	10
101	Direct or Collateral Liver Damage in SARS-CoV-2 [®] Infected Patients. <i>Seminars in Liver Disease</i> , 2020, 40, 321-330.	1.8	29
102	Drug repurposing approach to fight COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1479-1508.	1.5	323
103	The potential role of procyanidin as a therapeutic agent against SARS-CoV-2: a text mining, molecular docking and molecular dynamics simulation approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1230-1245.	2.0	34
104	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1428.	1.3	36
105	COVID-19: benefits and risks of passive immunotherapeutics. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2963-2972.	1.4	10
106	SARS [®] CoV [®] and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. <i>FASEB Journal</i> , 2020, 34, 14103-14119.	0.2	39
107	Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 101, 107716.	1.3	63
108	The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 813-814.	0.9	2

#	ARTICLE	IF	CITATIONS
109	A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp). <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-8.	2.0	20
110	Sex differences in severity and mortality from COVID-19: are males more vulnerable?. <i>Biology of Sex Differences</i> , 2020, 11, 53.	1.8	197
111	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6790.	1.8	52
112	Vaccine against COVID-19 or against SARS-CoV-2 infection?. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2020, 7, 131-145.	0.0	3
113	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. <i>Pathogens and Disease</i> , 2020, 78, .	0.8	17
114	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. <i>Viruses</i> , 2020, 12, 880.	1.5	116
115	Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome. <i>Scientific Reports</i> , 2020, 10, 14179.	1.6	80
116	Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3055-3060.	1.4	68
117	The Immune Response and Immunopathology of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 2037.	2.2	137
118	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. <i>Frontiers in Microbiology</i> , 2020, 11, 1818.	1.5	81
119	Neurological manifestations of coronavirus infections – a systematic review. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2057-2071.	1.7	59
120	Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. <i>Advanced Materials</i> , 2020, 32, e2004210.	11.1	65
121	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	154
122	Bibliometric Analysis on COVID-19: A Comparison of Research Between English and Chinese Studies. <i>Frontiers in Public Health</i> , 2020, 8, 477.	1.3	83
123	SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. <i>Journal of Infectious Diseases</i> , 2020, 222, 1974-1984.	1.9	96
124	Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction. <i>Molecules</i> , 2020, 25, 4133.	1.7	10
125	Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. <i>Scientific Reports</i> , 2020, 10, 14991.	1.6	286
126	Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design. <i>Scientific Data</i> , 2020, 7, 309.	2.4	26

#	ARTICLE	IF	CITATIONS
127	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. <i>MSphere</i> , 2020, 5, .	1.3	62
128	<scp>SARS-CoV</scp>'s multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. <i>IUBMB Life</i> , 2020, 72, 2313-2330.	1.5	10
129	Can data from paediatric cohorts solve the COVID-19 puzzle?. <i>PLoS Pathogens</i> , 2020, 16, e1008798.	2.1	10
130	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). <i>Journal of Molecular Medicine</i> , 2020, 98, 1369-1383.	1.7	30
131	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34
132	A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 186.	1.6	24
133	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	1.6	65
134	Screening the General Population for SARS-CoV-2 Virus and COVID-19 Antibodies: A Counterargument. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1107-1110.	0.6	9
135	Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. <i>Journal of Infectious Diseases</i> , 2020, 222, 1965-1973.	1.9	13
136	Deciphering SARS-CoV-2 Virologic and Immunologic Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5932.	1.8	28
137	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. <i>Microorganisms</i> , 2020, 8, 1250.	1.6	90
138	Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments. <i>Frontiers in Pharmacology</i> , 2020, 11, 595888.	1.6	44
139	A Potential Peptide From Soy Cheese Produced Using <i>Lactobacillus delbrueckii</i> WS4 for Effective Inhibition of SARS-CoV-2 Main Protease and S1 Glycoprotein. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 601753.	1.6	39
140	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 569760.	2.2	30
141	Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies. <i>Heliyon</i> , 2020, 6, e04658.	1.4	104
142	The viral protein fragment theory of COVID-19 pathogenesis. <i>Medical Hypotheses</i> , 2020, 144, 110267.	0.8	11
143	Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays. <i>Pathology</i> , 2020, 52, 770-777.	0.3	37
144	<scp>COVID</scp>-19, microthromboses, inflammation, and platelet activating factor. <i>BioFactors</i> , 2020, 46, 927-933.	2.6	50

#	ARTICLE	IF	CITATIONS
145	Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in <i>Pichia pastoris</i> and mammalian cells. <i>Scientific Reports</i> , 2020, 10, 21779.	1.6	89
146	Chasing COVID-19 through SARS-CoV-2 spike glycoprotein. <i>VirusDisease</i> , 2020, 31, 399-407.	1.0	13
147	Anisotone and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 4532-4542.	2.0	35
148	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. <i>Science Immunology</i> , 2020, 5, .	5.6	404
149	Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 591873.	1.6	83
150	Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. <i>Cells</i> , 2020, 9, 2638.	1.8	138
151	Animal coronaviruses and coronavirus disease 2019: Lesson for One Health approach. <i>Open Veterinary Journal</i> , 2020, 10, 239-251.	0.3	15
152	Coevolution, Dynamics and Allosteric Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8268.	1.8	37
153	SARS-CoV-2 mutations and where to find them: an <i>in silico</i> perspective of structural changes and antigenicity of the spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 3336-3346.	2.0	1
154	Hyperthrombotic Milieu in COVID-19 Patients. <i>Cells</i> , 2020, 9, 2392.	1.8	27
155	Novel Evidence of Acute Kidney Injury in COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3547.	1.0	39
156	Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity <i>in vitro</i> and with clinical implications <i>in vivo</i> . <i>Cell Discovery</i> , 2020, 6, 76.	3.1	72
157	Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. <i>Microbial Pathogenesis</i> , 2020, 145, 104236.	1.3	154
158	A global treatments for coronaviruses including COVID-19. <i>Journal of Cellular Physiology</i> , 2020, 235, 9133-9142.	2.0	91
159	Current development of COVID-19 diagnostics, vaccines and therapeutics. <i>Microbes and Infection</i> , 2020, 22, 231-235.	1.0	44
160	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102174.	0.9	62
161	Coronavirus Disease 2019 and the Cerebrovascular-Cardiovascular Systems: What Do We Know So Far?. <i>Journal of the American Heart Association</i> , 2020, 9, e016793.	1.6	31
162	Certainty of success: three critical parameters in coronavirus vaccine development. <i>Npj Vaccines</i> , 2020, 5, 42.	2.9	18

#	ARTICLE	IF	CITATIONS
163	Therapeutic Plasma Exchangeâ€œNeutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2020, 222, 509-510.	1.9	0
164	Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. <i>Antiviral Research</i> , 2020, 179, 104820.	1.9	106
165	Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?. <i>Cell Calcium</i> , 2020, 88, 102212.	1.1	31
166	COVIDâ€™19: Focus on the lungs but do not forget the gastrointestinal tract. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13276.	1.7	45
167	Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. <i>Journal of Virology</i> , 2020, 94, .	1.5	148
168	Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Is Comparable in Clinical Samples Preserved in Saline or Viral Transport Medium. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 871-875.	1.2	43
169	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
170	Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. <i>Cellular and Molecular Immunology</i> , 2020, 17, 621-630.	4.8	413
171	Role and mechanism of angiotensinâ€™converting enzyme 2 in acute lung injury in coronavirus disease 2019. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 98-105.	0.9	34
172	SARS-CoV-2 infection serology: a useful tool to overcome lockdown?. <i>Cell Death Discovery</i> , 2020, 6, 38.	2.0	65
173	Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3664.	1.2	47
174	Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104382.	1.0	36
175	Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 4785-4790.	2.1	147
176	Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. <i>PLoS ONE</i> , 2020, 15, e0233947.	1.1	94
177	Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system. <i>Biochemical and Biophysical Research Communications</i> , 2020, 529, 257-262.	1.0	40
178	Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug. <i>Life Sciences</i> , 2020, 256, 117970.	2.0	45
179	Tackling SARS-CoV-2: proposed targets and repurposed drugs. <i>Future Medicinal Chemistry</i> , 2020, 12, 1579-1601.	1.1	46
180	Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. <i>Chemical Communications</i> , 2020, 56, 8683-8686.	2.2	34

#	ARTICLE	IF	CITATIONS
181	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3843.	1.8	37
182	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. <i>Emerging Microbes and Infections</i> , 2020, 9, 1397-1406.	3.0	49
183	SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. <i>Journal of Translational Medicine</i> , 2020, 18, 222.	1.8	158
184	Ten things we learned about COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 1590-1593.	3.9	28
185	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. <i>Heart Lung and Circulation</i> , 2020, 29, 973-987.	0.2	136
186	Diacerein: A potential multi-target therapeutic drug for COVID-19. <i>Medical Hypotheses</i> , 2020, 144, 109920.	0.8	27
187	Biomarkers associated with COVID-19 disease progression. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 389-399.	2.7	570
188	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1441.	2.2	515
189	The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach. <i>Journal of Proteome Research</i> , 2020, 19, 4576-4586.	1.8	66
190	COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response. <i>Open Heart</i> , 2020, 7, e001302.	0.9	9
191	Natural compounds from <i>Clerodendrum</i> spp. as possible therapeutic candidates against SARS-CoV-2: An <i>in silico</i> investigation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 4774-4785.	2.0	57
192	Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	180
193	Genomic analysis and comparative multiple sequences of SARS-CoV2. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 537-543.	0.6	40
194	COVID 19: a clue from innate immunity. <i>Immunologic Research</i> , 2020, 68, 161-168.	1.3	117
195	Out of the Darkness, Into the Light: Value of SARS-CoV-2 Antibody Testing in Populations to Benefit Public Health and in Individuals for Peace of Mind. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 1101-1106.	0.6	0
196	Drug targets for COVID-19 therapeutics: Ongoing global efforts. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	69
197	A contemporary review on pathogenesis and immunity of COVID-19 infection. <i>Molecular Biology Reports</i> , 2020, 47, 5365-5376.	1.0	38
198	Betacoronavirus Genomes: How Genomic Information has been Used to Deal with Past Outbreaks and the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4546.	1.8	34

#	ARTICLE	IF	CITATIONS
200	Could Sex/Gender Differences in ACE2 Expression in the Lungs Contribute to the Large Gender Disparity in the Morbidity and Mortality of Patients Infected With the SARS-CoV-2 Virus?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 327.	1.8	32
201	Evidence for SARS-CoV-2 Infection of Animal Hosts. <i>Pathogens</i> , 2020, 9, 529.	1.2	167
202	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. <i>European Journal of Pharmacology</i> , 2020, 883, 173348.	1.7	55
203	Progress in the Research and Development of Anti-COVID-19 Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 365.	1.3	21
204	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 32, 107918.	2.9	148
205	Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells. <i>Drugs in R and D</i> , 2020, 20, 161-169.	1.1	80
206	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. <i>Vaccines</i> , 2020, 8, 335.	2.1	43
207	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Journal of Immunology</i> , 2020, 205, 915-922.	0.4	186
208	Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. <i>Virus Research</i> , 2020, 288, 198082.	1.1	56
209	Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5690-5705.	2.0	39
210	Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5706-5721.	2.0	18
211	COVID-19: Progress in diagnostics, therapy and vaccination. <i>Theranostics</i> , 2020, 10, 7821-7835.	4.6	121
212	An updated analysis of variations in SARS-CoV-2 genome. <i>Turkish Journal of Biology</i> , 2020, 44, 157-167.	2.1	55
213	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. <i>Drug Development Research</i> , 2020, 81, 919-941.	1.4	35
214	The trinity of COVID-19: immunity, inflammation and intervention. <i>Nature Reviews Immunology</i> , 2020, 20, 363-374.	10.6	3,347
215	COVID-19 vaccine design: the Janus face of immune enhancement. <i>Nature Reviews Immunology</i> , 2020, 20, 347-348.	10.6	155
216	Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal-Oral Transmission? A COVID-19 Virological and Clinical Review. <i>Gastroenterology</i> , 2020, 159, 53-61.	0.6	157
217	Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2020, 55, 2001023.	3.1	56

#	ARTICLE	IF	CITATIONS
218	Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. <i>Physiological Genomics</i> , 2020, 52, 217-221.	1.0	82
219	The possible of immunotherapy for COVID-19: A systematic review. <i>International Immunopharmacology</i> , 2020, 83, 106455.	1.7	104
220	Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. <i>Trends in Immunology</i> , 2020, 41, 355-359.	2.9	677
221	COVID-19: A promising cure for the global panic. <i>Science of the Total Environment</i> , 2020, 725, 138277.	3.9	464
222	Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. <i>Frontiers in Immunology</i> , 2020, 11, 879.	2.2	218
223	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 1131.	1.0	112
224	The Use of CaptoprilâAngiotensin Converting Enzyme (ACE) Inhibitor for Cystinuria During COVID-19 Pandemic. <i>Urology</i> , 2020, 141, 182-183.	0.5	5
225	<scp>COVID</scp>â19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. <i>BioFactors</i> , 2020, 46, 306-308.	2.6	107
226	<scp>DPP4</scp> inhibition: Preventing <scp>SARSâCoV</scp>â2 infection and/or progression of <scp>COVID</scp>â19?. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3330.	1.7	95
227	Emerging genetic diversity among clinical isolates of SARS-CoV-2: Lessons for today. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104330.	1.0	54
228	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 407-412.	1.8	759
229	A short review on antibody therapy for COVID-19. <i>New Microbes and New Infections</i> , 2020, 35, 100682.	0.8	51
230	Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. <i>American Journal of Emergency Medicine</i> , 2020, 44, 352-357.	0.7	158
231	An update on the origin of SARSâCoVâ2: Despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and Oâlinked glycan residues. <i>Journal of Medical Virology</i> , 2021, 93, 499-505.	2.5	43
232	Development of a robust Escherichia coli-based cell-free protein synthesis application platform. <i>Biochemical Engineering Journal</i> , 2021, 165, 107830.	1.8	14
233	A diagnostic genomic signal processing (GSP)-based system for automatic feature analysis and detection of COVID-19. <i>Briefings in Bioinformatics</i> , 2021, 22, 1197-1205.	3.2	27
234	Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. <i>Infection, Genetics and Evolution</i> , 2021, 89, 104490.	1.0	79
235	SARSâCoVâ2 S1 is superior to the RBD as a COVIDâ19 subunit vaccine antigen. <i>Journal of Medical Virology</i> , 2021, 93, 892-898.	2.5	77

#	ARTICLE	IF	CITATIONS
236	Children were less frequently infected with SARS-CoV-2 than adults during 2020 COVID-19 pandemic in Warsaw, Poland. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 541-547.	1.3	18
237	Thrombotic complications of COVID-19. <i>American Journal of Emergency Medicine</i> , 2021, 39, 213-218.	0.7	106
238	Binding of SARS-CoV-2 to Cell Receptors: A Tale of Molecular Evolution. <i>ChemBioChem</i> , 2021, 22, 724-732.	1.3	27
239	Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100058.	2.5	105
240	Is a healthy microbiome responsible for lower mortality in COVID-19?. <i>Biologia (Poland)</i> , 2021, 76, 819-829.	0.8	24
241	Pathogenesis-directed therapy of 2019 novel coronavirus disease. <i>Journal of Medical Virology</i> , 2021, 93, 1320-1342.	2.5	40
242	Severe acute respiratory syndrome-coronavirus spike (S) protein based vaccine candidates: State of the art and future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2183.	3.9	43
243	Epidemiology and diagnosis, environmental resources quality and socio-economic perspectives for COVID-19 pandemic. <i>Journal of Environmental Management</i> , 2021, 280, 111700.	3.8	53
244	Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10202.	3.9	35
245	SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. <i>Vascular Pharmacology</i> , 2021, 137, 106823.	1.0	64
246	Current methods for diagnosis of human coronaviruses: pros and cons. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 2311-2330.	1.9	47
247	SARS-CoV-2: a new dimension to our understanding of coronaviruses. <i>International Microbiology</i> , 2021, 24, 19-24.	1.1	25
248	Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein. <i>Theranostics</i> , 2021, 11, 649-664.	4.6	43
249	Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1179-1193.	1.4	41
250	A review of COVID-19 vaccines and major considerations for diabetic patients. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 30-40.	1.4	6
251	Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2021, 18, 487-489.	4.8	115
252	Neutralizing antibodies targeting SARS-CoV-2 spike protein. <i>Stem Cell Research</i> , 2021, 50, 102125.	0.3	89
253	Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. <i>Journal of Proteome Research</i> , 2021, 20, 49-59.	1.8	32

#	ARTICLE	IF	CITATIONS
254	Usage of peptidases by SARS-CoV-2 and several human coronaviruses as receptors: A mysterious story. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 124-128.	1.4	10
255	Coevolutionary forces shaping the fitness of SARS-CoV-2 spike glycoprotein against human receptor ACE2. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104646.	1.0	16
256	SARS-CoV-2 in hospital wastewater during outbreak of COVID-19: A review on detection, survival and disinfection technologies. <i>Science of the Total Environment</i> , 2021, 761, 143192.	3.9	69
257	SARS-CoV-2 vaccine candidates in rapid development. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 644-653.	1.4	30
258	The Cellular basis of loss of smell in 2019-nCoV-infected individuals. <i>Briefings in Bioinformatics</i> , 2021, 22, 873-881.	3.2	41
259	Single-cell RNA sequencing analysis of SARS-CoV-2 entry receptors in human organoids. <i>Journal of Cellular Physiology</i> , 2021, 236, 2950-2958.	2.0	19
260	Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. <i>Angiology</i> , 2021, 72, 122-130.	0.8	20
261	Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. <i>Journal of Cellular Physiology</i> , 2021, 236, 2364-2392.	2.0	65
262	Origin-independent analysis links SARS-CoV-2 local genomes with COVID-19 incidence and mortality. <i>Briefings in Bioinformatics</i> , 2021, 22, 905-913.	3.2	1
263	Management of SARS-CoV-2 pneumonia. <i>Journal of Medical Virology</i> , 2021, 93, 1276-1287.	2.5	22
265	Application of Nanotechnology in the COVID-19 Pandemic. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 623-649.	3.3	60
266	Emerging Trends of Bioinformatics in Health Informatics. <i>Health Information Science</i> , 2021, , 343-367.	0.3	2
267	Introduction to the Virus and Its Infection Stages. , 2021, , 1-26.		0
268	Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy. <i>International Journal of Biological Sciences</i> , 2021, 17, 2957-2969.	2.6	11
269	Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa. <i>Heliyon</i> , 2021, 7, e06035.	1.4	25
270	EpiSurf: metadata-driven search server for analyzing amino acid changes within epitopes of SARS-CoV-2 and other viral species. <i>Database: the Journal of Biological Databases and Curation</i> , 2021, ,	1.4	6
271	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. <i>Nature Communications</i> , 2021, 12, 324.	5.8	79
272	Innovative Strategies to Understand and Control COVID-19 Disease. <i>Algorithms for Intelligent Systems</i> , 2021, , 209-230.	0.5	0

#	ARTICLE	IF	CITATIONS
273	Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19. <i>GeroScience</i> , 2021, 43, 19-29.	2.1	24
274	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. <i>Open Life Sciences</i> , 2021, 16, 558-570.	0.6	8
275	Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles. <i>Colloids and Interface Science Communications</i> , 2021, 40, 100356.	2.0	10
278	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 905-919.	1.3	445
279	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	5.3	134
280	COVID-19 and SARS-CoV-2: Everything we know so far – a comprehensive review. <i>Open Chemistry</i> , 2021, 19, 548-575.	1.0	6
281	Computational Modeling of ACE2-Mediated Cell Entry Inhibitors for the Development of Drugs Against Coronaviruses. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 495.	0.1	1
283	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. <i>Scientific Reports</i> , 2021, 11, 2608.	1.6	86
284	Horizontal gene transfer and recombination analysis of SARS-CoV-2 genes helps discover its close relatives and shed light on its origin. <i>Bmc Ecology and Evolution</i> , 2021, 21, 5.	0.7	44
285	Structure of SARS CoV2. <i>SpringerBriefs in Applied Sciences and Technology</i> , 2021, , 11-24.	0.2	1
286	Possible host-adaptation of SARS-CoV-2 due to improved ACE2 receptor binding in mink. <i>Virus Evolution</i> , 2021, 7, veaa094.	2.2	50
287	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. <i>Viruses</i> , 2021, 13, 134.	1.5	56
288	HVIDB: a comprehensive database for human-virus protein-protein interactions. <i>Briefings in Bioinformatics</i> , 2021, 22, 832-844.	3.2	48
289	COVID-19 Pandemic and Vaccines. , 2021, , 205-235.		2
290	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1661-1671.	1.9	7
291	Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 467-476.	1.9	25
293	Molecular characterization of COVID-19 therapeutics: luteolin as an allosteric modulator of the spike protein of SARS-CoV-2. <i>Molecular Systems Design and Engineering</i> , 2022, 7, 58-66.	1.7	11
294	Bats, pangolins, minks and other animals - villains or victims of SARS-CoV-2?. <i>Veterinary Research Communications</i> , 2021, 45, 1-19.	0.6	41

#	ARTICLE	IF	CITATIONS
295	3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor. <i>Frontiers in Pharmacology</i> , 2020, 11, 603830.	1.6	3
296	Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 5138-5146.	2.0	29
297	Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. <i>Reviews in Medical Virology</i> , 2021, 31, 1-13.	3.9	40
298	The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19). <i>Theranostics</i> , 2021, 11, 6193-6213.	4.6	16
299	Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. <i>Bioinformatics and Biology Insights</i> , 2021, 15, 117793222110258.	1.0	84
300	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 36.	2.1	41
302	Autoimmune Processes Involved in Organ System Failure Following Infection with SARS-CoV-2. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 355-368.	0.8	0
303	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. <i>Nature Communications</i> , 2021, 12, 288.	5.8	224
304	Posterior Reversible Encephalopathy Syndrome (PRES) and Meningo-Encephalitis in COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 227-237.		0
305	Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1285.	1.7	45
306	Jackfruit Seed Extract Exposure on Zebrafish Embryos as Initial Screening Model for Covid-19 Treatment. <i>Journal of Infection and Public Health</i> , 2021, 14, 227-237.		0
307	Use of Bioinformatics Technologies and Databases to Teach Analysis of Genetic Sequences to Undergraduate Students in Physics, Biotechnology, and Biology: The Specific Case of the SARS-CoV-2 Spike Protein. <i>Creative Education</i> , 2021, 12, 193-202.	0.2	2
308	Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2. <i>Journal of Infection and Public Health</i> , 2021, 14, 227-237.	1.9	11
309	Analysis of the COVID-19 Vaccine Development Process: an Exploratory Study of Accelerating Factors and Innovative Environments. <i>Journal of Pharmaceutical Innovation</i> , 2022, 17, 555-571.	1.1	29
310	A review on the effect of COVID-19 in type 2 asthma and its management. <i>International Immunopharmacology</i> , 2021, 91, 107309.	1.7	17
311	Altitude conditions seem to determine the evolution of COVID-19 in Brazil. <i>Scientific Reports</i> , 2021, 11, 4402.	1.6	18
312	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100193.	3.3	37
313	Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan. <i>PLoS ONE</i> , 2021, 16, e0246383.	1.1	29

#	ARTICLE	IF	CITATIONS
315	Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6545-6555.	2.0	40
316	Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation. <i>Current Stem Cell Research and Therapy</i> , 2021, 16, 189-198.	0.6	1
317	COVID-19: Molecular and Cellular Response. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 563085.	1.8	31
318	A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation. <i>Frontiers in Immunology</i> , 2021, 12, 637654.	2.2	17
319	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2268.	1.8	24
320	Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19. <i>Heliyon</i> , 2021, 7, e06350.	1.4	86
321	Potential bioactive compounds of medicinal plants against new Coronavirus (SARS-CoV-2): A review. <i>Revista Bionatura</i> , 2021, 6, 1653-1658.	0.1	9
322	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review. <i>Archives of Microbiology</i> , 2021, 203, 2043-2057.	1.0	9
323	SARS-CoV-2 and endothelial cell interaction in COVID-19: molecular perspectives. <i>Vascular Biology (Bristol, England)</i> , 2021, 3, R15-R23.	1.2	31
324	Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 640093.	2.2	93
325	Population Genomics Insights into the First Wave of COVID-19. <i>Life</i> , 2021, 11, 129.	1.1	14
327	Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. <i>PLoS Pathogens</i> , 2021, 17, e1009165.	2.1	40
328	COVID-19 patients may become predisposed to pulmonary arterial hypertension. <i>Medical Hypotheses</i> , 2021, 147, 110483.	0.8	37
329	Innate Immune Cells and Hypertension: Neutrophils and Neutrophil Extracellular Traps (NETs). , 2021, 11, 1575-1589.		23
330	Molecular recognition in the infection, replication, and transmission of COVID-19-causing SARS-CoV-2: an emerging interface of infectious disease, biological chemistry, and nanoscience. <i>NPG Asia Materials</i> , 2021, 13, .	3.8	15
331	Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1659.	1.8	16
332	Rapid SARS-CoV-2 Spike Protein Detection by Carbon Nanotube-Based Near-Infrared Nanosensors. <i>Nano Letters</i> , 2021, 21, 2272-2280.	4.5	139
333	Genomic mutations and changes in protein secondary structure and solvent accessibility of SARS-CoV-2 (COVID-19 virus). <i>Scientific Reports</i> , 2021, 11, 3487.	1.6	62

#	ARTICLE	IF	CITATIONS
334	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. <i>International Reviews of Immunology</i> , 2022, 41, 171-206.	1.5	30
335	Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBDN318-V510) Expressed in <i>Escherichia coli</i> . <i>Diagnostics</i> , 2021, 11, 271.	1.3	17
336	Neurobiology of COVID-19: how can the virus affect the brain?. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 650-664.	0.9	31
337	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43
338	Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1913.	1.8	11
339	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 574425.	2.2	38
341	Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1687.	1.8	61
343	Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2. <i>Journal of Medical Virology</i> , 2021, 93, 3143-3151.	2.5	33
344	Ca ²⁺ -dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide. <i>Biophysical Journal</i> , 2021, 120, 1105-1119.	0.2	53
345	Neurological Complications in COVID-19: Implications on International Health Security and Possible Interventions of Phytochemicals. , 0, , .		4
346	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 63-85.	2.7	40
347	The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development. <i>Probiotics and Antimicrobial Proteins</i> , 2021, 13, 1239-1253.	1.9	20
350	Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. <i>European Journal of Pharmacology</i> , 2021, 894, 173836.	1.7	51
351	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 104, 441-451.	1.5	14
352	ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species. <i>Nature Ecology and Evolution</i> , 2021, 5, 600-608.	3.4	83
354	Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. <i>Journal of Structural Biology</i> , 2021, 213, 107690.	1.3	8
355	A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48
356	Damage of the Muscle System in Covid-19. <i>Russian Archives of Internal Medicine</i> , 2021, 11, 146-153.	0.0	3

#	ARTICLE	IF	CITATIONS
358	A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6671-6681.	2.0	5
359	Overcoming the Challenge of Communicating the Concept and Science of SARS-CoV-2 and COVID-19 to Non-Experts. <i>Challenge</i> , 2021, 64, 117-131.	0.4	6
360	Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. <i>Scientific Reports</i> , 2021, 11, 5975.	1.6	26
361	COVID-19: Potential Repurposing Drugs. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	4
362	SARS-CoV 2 in Cellular Level: Do we dominate the whole picture and how can we intervene?. <i>Journal of Contemporary Medicine</i> , 2021, 11, 248-253.	0.1	0
364	A Multifunctional Peptide From Bacillus Fermented Soybean for Effective Inhibition of SARS-CoV-2 S1 Receptor Binding Domain and Modulation of Toll Like Receptor 4: A Molecular Docking Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 636647.	1.6	26
365	MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 5376.	1.6	18
366	Immunogenetic Predictors of Severe COVID-19. <i>Vaccines</i> , 2021, 9, 211.	2.1	40
367	An overview of vaccine development for COVID-19. <i>Therapeutic Delivery</i> , 2021, 12, 235-244.	1.2	51
369	Recombinant protein vaccines, a proven approach against coronavirus pandemics. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 71-82.	6.6	157
370	A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing. <i>PLoS ONE</i> , 2021, 16, e0248553.	1.1	17
371	Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection. <i>Angewandte Chemie</i> , 2021, 133, 10361-10366.	1.6	15
372	Bell's Palsy as a Late Neurologic Manifestation of COVID-19 Infection. <i>Cureus</i> , 2021, 13, e13881.	0.2	10
373	Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10273-10278.	7.2	81
374	Heterogeneity of Glycan Processing on Trimeric SARS-CoV-2 Spike Protein Revealed by Charge Detection Mass Spectrometry. <i>Journal of the American Chemical Society</i> , 2021, 143, 3959-3966.	6.6	45
375	Comparative sequence analysis of SARS-CoV-2 suggests its high transmissibility and pathogenicity. <i>Future Virology</i> , 2021, 16, 245-254.	0.9	9
376	1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 634176.	1.6	28
377	Frontrunners in the race to develop a SARS-CoV-2 vaccine. <i>Canadian Journal of Microbiology</i> , 2021, 67, 189-212.	0.8	11

#	ARTICLE	IF	CITATIONS
378	Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation. <i>Heliyon</i> , 2021, 7, e06435.	1.4	11
379	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. <i>Stem Cell Reports</i> , 2021, 16, 398-411.	2.3	18
380	Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. <i>Biophysical Journal</i> , 2021, 120, 1011-1019.	0.2	87
381	A Review of the Animal and Human Trials of the Ad5-nCoV Vaccine Candidate. <i>Journal of Student Research</i> , 2021, 10, .	0.0	2
382	Research progress on coronavirus S proteins and their receptors. <i>Archives of Virology</i> , 2021, 166, 1811-1817.	0.9	6
383	Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice. <i>Journal of the American Heart Association</i> , 2021, 10, e019506.	1.6	8
385	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 113-141.	6.6	71
386	Whole-genome sequencing of SARS-CoV-2 reveals the detection of G614 variant in Pakistan. <i>PLoS ONE</i> , 2021, 16, e0248371.	1.1	34
387	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
388	Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 192-199.	0.9	2
389	Cardiorenal syndrome in COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e241914.	0.2	4
390	COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7885-7898.	2.0	14
391	Vaccine Development Against SARS-CoV-2: From Virology to Vaccine Clinical Trials. <i>Coronaviruses</i> , 2021, 2, 159-171.	0.2	4
392	Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening". <i>PLoS ONE</i> , 2021, 16, e0250319.	1.1	14
393	Recent advances in nanomaterials based biosensors for point of care (PoC) diagnosis of Covid-19 " A minireview. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 137, 116205.	5.8	85
394	A novel pseudovirus-based mouse model of SARS-CoV-2 infection to test COVID-19 interventions. <i>Journal of Biomedical Science</i> , 2021, 28, 34.	2.6	23
395	NeutrobodyPlex" monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. <i>EMBO Reports</i> , 2021, 22, e52325.	2.0	43
396	SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia. <i>Frontiers in Immunology</i> , 2021, 12, 656700.	2.2	49

#	ARTICLE	IF	CITATIONS
397	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1-15.	2.5	6
400	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. <i>Journal of Physical Chemistry B</i> , 2021, 125, 4596-4619.	1.2	60
401	Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 647295.	1.5	24
402	Strategies for Immunomonitoring after Vaccination and during Infection. <i>Vaccines</i> , 2021, 9, 365.	2.1	12
403	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. <i>PLoS Pathogens</i> , 2021, 17, e1009064.	2.1	21
404	Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. <i>Vaccines</i> , 2021, 9, 395.	2.1	32
405	Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant <i>Glycyrrhiza glabra</i> with SARS CoV-2 main protease. <i>Food and Chemical Toxicology</i> , 2021, 150, 112057.	1.8	17
406	Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach. <i>Qatar Medical Journal</i> , 2021, 2021, 12.	0.2	11
408	Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus. <i>Genome</i> , 2021, 64, 386-399.	0.9	58
409	Effect of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) on reproductive system. <i>Stem Cell Research</i> , 2021, 52, 102189.	0.3	15
410	Covid-19 Tedavisinde İmmun Plazma Uygulamaları. Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 2021, 17, 1-10.	0.0	0
412	Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. <i>Biosensors and Bioelectronics</i> , 2021, 177, 112969.	5.3	22
413	SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 1-15.	3.2	84
415	COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes. <i>European Journal of Pharmacology</i> , 2021, 896, 173930.	1.7	23
416	Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. <i>ACS Central Science</i> , 2021, 7, 757-767.	5.3	46
417	Nano-size dependence in the adsorption by the SARS-CoV-2 spike protein over gold colloid. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2021, 615, 126275.	2.3	10
418	COVID-19: insights into virus-receptor interactions. <i>Molecular Biomedicine</i> , 2021, 2, 10.	1.7	8
420	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484.	1.2	62

#	ARTICLE	IF	CITATIONS
421	Fundamental evolution of all <i>Orthocoronavirinae</i> including three deadly lineages descendent from Chiroptera-hosted coronaviruses: SARS-CoV, MERS-CoV and SARS-CoV-2. <i>Cladistics</i> , 2021, 37, 461-488.	1.5	16
422	Human cell receptors: potential drug targets to combat COVID-19. <i>Amino Acids</i> , 2021, 53, 813-842.	1.2	21
425	Perspective: the nose and the stomach play a critical role in the N2ACE2-P2ari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 553-560.	1.3	10
426	BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2895-2998.	2.7	29
427	The role and significance of angiotensin-converting enzyme 2 peptides in the treatment of coronavirus disease 2019. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23789.	0.9	4
428	Targeting the viral entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 5260-5276.	2.5	26
429	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. <i>Archives of Pharmacal Research</i> , 2021, 44, 499-513.	2.7	18
430	Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 641447.	2.2	20
431	Targets and strategies for vaccine development against SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111254.	2.5	58
432	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting with Undetectable Toxicity. <i>Chemical Reviews</i> , 2021, 121, 7398-7467.	23.0	45
433	Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 670815.	1.6	17
434	Placental Sampling for Understanding Viral Infections - A Simplified Protocol for the COVID-19 Pandemic. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 377-383.	0.3	4
435	Plausible blockers of Spike RBD in SARS-CoV-2-molecular design and underlying interaction dynamics from high-level structural descriptors. <i>Journal of Molecular Modeling</i> , 2021, 27, 191.	0.8	10
436	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	0.4	12
438	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. <i>ACS Central Science</i> , 2021, 7, 1001-1008.	5.3	47
439	SARS-CoV-2 and its Predicted Potential Natural Inhibitors: A Review and Perspective. <i>Coronaviruses</i> , 2021, 2, .	0.2	1
440	Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from <i>Escherichia coli</i> . <i>Engineering in Life Sciences</i> , 2021, 21, 453-460.	2.0	38
441	The interplay between the immune system and SARS-CoV-2 in COVID-19 patients. <i>Archives of Virology</i> , 2021, 166, 2109-2117.	0.9	7

#	ARTICLE	IF	CITATIONS
442	Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. <i>Vaccines</i> , 2021, 9, 466.	2.1	30
443	Should We Be Concerned about the Association of Diabetes Mellitus and Periodontal Disease in the Risk of Infection by SARS-CoV-2? A Systematic Review and Hypothesis. <i>Medicina (Lithuania)</i> , 2021, 57, 493.	0.8	9
444	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. <i>Viruses</i> , 2021, 13, 927.	1.5	29
446	Evolution of SARS CoV-2 Coronavirus Surface Protein Investigated with Mass Spectrometry Based Phylogenetics. <i>Analytical Letters</i> , 0, , 1-13.	1.0	6
447	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
448	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1519-1534.	1.8	77
449	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. <i>Biosensors and Bioelectronics</i> , 2021, 180, 113122.	5.3	21
450	Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2824-2840.	1.4	7
451	Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD). <i>Natural Product Research</i> , 2022, 36, 5358-5363.	1.0	19
452	Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 11046.	1.6	13
455	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , 2021, 35, 109109.	2.9	21
456	Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1743-1765.	0.8	21
458	Spike protein fusion loop controls SARS-CoV-2 fusogenicity and infectivity. <i>Journal of Structural Biology</i> , 2021, 213, 107713.	1.3	11
459	Landscape and selection of vaccine epitopes in SARS-CoV-2. <i>Genome Medicine</i> , 2021, 13, 101.	3.6	30
460	Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5729-5741.	2.5	37
461	A brief molecular insight of COVID-19: epidemiology, clinical manifestation, molecular mechanism, cellular tropism and immuno-pathogenesis. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 3987-4002.	1.4	6
462	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. <i>Frontiers in Immunology</i> , 2021, 12, 658519.	2.2	63
463	Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2. <i>Gene Reports</i> , 2021, 23, 101064.	0.4	29

#	ARTICLE	IF	CITATIONS
464	Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery. <i>Future Virology</i> , 2021, 16, 389-397.	0.9	10
465	Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. <i>Pharmacological Reports</i> , 2021, 73, 1539-1550.	1.5	48
466	Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. <i>Frontiers in Immunology</i> , 2021, 12, 708523.	2.2	70
467	Attractive and repulsive residue fragments at the interface of SARS-CoV-2 and hACE2. <i>Scientific Reports</i> , 2021, 11, 12567.	1.6	5
468	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
469	More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6462.	1.8	14
470	Evolutionary selectivity of amino acid is inspired from the enhanced structural stability and flexibility of the folded protein. <i>Life Sciences</i> , 2021, 281, 119774.	2.0	7
471	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. <i>Molecular Therapy</i> , 2021, 29, 1984-2000.	3.7	19
472	Efficient Identification of High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1221-1227.	1.2	0
473	Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells. <i>Genome</i> , 2021, 64, 595-598.	0.9	7
474	Landscape-Based Mutational Sensitivity Cartography and Network Community Analysis of the SARS-CoV-2 Spike Protein Structures: Quantifying Functional Effects of the Circulating D614G Variant. <i>ACS Omega</i> , 2021, 6, 16216-16233.	1.6	10
475	Advances in Neutralization Assays for SARS-CoV-2. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13088.	1.3	40
476	Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options. <i>Coronaviruses</i> , 2021, 2, 481-491.	0.2	17
477	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. <i>Covid</i> , 2021, 1, 20-38.	0.7	22
478	Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID). <i>International Journal of Molecular Sciences</i> , 2021, 22, 6937.	1.8	20
479	Regulated Intramembrane Proteolysis of ACE2: A Potential Mechanism Contributing to COVID-19 Pathogenesis?. <i>Frontiers in Immunology</i> , 2021, 12, 612807.	2.2	13
480	Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 3262-3269.	1.8	12
481	Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 5987-5993.	2.1	33

#	ARTICLE	IF	CITATIONS
482	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3575-3583.	2.0	41
483	A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. <i>International Journal of Biological Macromolecules</i> , 2021, 181, 605-611.	3.6	20
484	Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera. <i>Viruses</i> , 2021, 13, 1133.	1.5	19
485	Dynamics of Antibodies to Various Antigens of the SARS-CoV-2 Coronavirus in Patients with Confirmed COVID-19 Infection. <i>Bulletin of Experimental Biology and Medicine</i> , 2021, 171, 230-233.	0.3	2
486	Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. <i>Cell</i> , 2021, 184, 3192-3204.e16.	13.5	68
487	Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129893.	1.1	49
488	Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein. <i>ACS Omega</i> , 2021, 6, 15988-15999.	1.6	32
489	Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 320, R925-R937.	0.9	10
490	The Role of Indoor Plants in air Purification and Human Health in the Context of COVID-19 Pandemic: A Proposal for a Novel Line of Inquiry. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 709395.	1.6	8
491	In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. <i>BioMed Research International</i> , 2021, 2021, 1-21.	0.9	9
492	AI-guided discovery of the invariant host response to viral pandemics. <i>EBioMedicine</i> , 2021, 68, 103390.	2.7	37
493	Computational analysis of protein stability and allosteric interaction networks in distinct conformational forms of the SARS-CoV-2 spike D614G mutant: reconciling functional mechanisms through allosteric model of spike regulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9724-9741.	2.0	11
494	Piezoelectric MEMS Micro-Cantilever Biosensor for Detection of SARS-CoV-2. , 2021, , .		4
495	SARS-CoV2 RBD gene transcription cannot be driven by CMV promoter. <i>Virology</i> , 2021, 558, 22-27.	1.1	2
496	A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0019321.	1.8	20
497	Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-CoV-2 infection. <i>Journal of Controlled Release</i> , 2021, 335, 584-595.	4.8	29
498	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. <i>Biochemistry</i> , 2021, 60, 2153-2169.	1.2	54
499	Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2836-2847.	2.9	22

#	ARTICLE	IF	CITATIONS
500	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. <i>Frontiers in Immunology</i> , 2021, 12, 701501.	2.2	157
501	Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. <i>Infection, Genetics and Evolution</i> , 2021, 91, 104815.	1.0	8
502	Prophylactic and therapeutic potential of selected immunomodulatory agents from Ayurveda against coronaviruses amidst the current formidable scenario: an <i>in silico</i> analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9648-9700.	2.0	8
503	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. <i>Kidney International Reports</i> , 2021, 6, 1799-1809.	0.4	13
504	Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. <i>Scientific Reports</i> , 2021, 11, 14917.	1.6	23
505	Prediction of Drug-Induced Liver Toxicity Using SVM and Optimal Descriptor Sets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8073.	1.8	15
507	Role of host factors in SARS-CoV-2 entry. <i>Journal of Biological Chemistry</i> , 2021, 297, 100847.	1.6	67
508	Genetic emergence of B.1.617.2 in COVID-19. <i>New Microbes and New Infections</i> , 2021, 43, 100929.	0.8	45
509	New perspective towards therapeutic regimen against SARS-CoV-2 infection. <i>Journal of Infection and Public Health</i> , 2021, 14, 852-862.	1.9	3
510	COVID-19 versus SARS: A comparative review. <i>Journal of Infection and Public Health</i> , 2021, 14, 967-977.	1.9	5
511	Small molecule therapeutics to destabilize the ACE2-RBD complex: A molecular dynamics study. <i>Biophysical Journal</i> , 2021, 120, 2793-2804.	0.2	17
512	Enhanced sampling protocol to elucidate fusion peptide opening of SARS-CoV-2 spike protein. <i>Biophysical Journal</i> , 2021, 120, 2848-2858.	0.2	7
513	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. <i>Infection</i> , 2022, 50, 11-25.	2.3	50
514	Development of flexible electrochemical impedance spectroscopy-based biosensing platform for rapid screening of SARS-CoV-2 inhibitors. <i>Biosensors and Bioelectronics</i> , 2021, 183, 113213.	5.3	44
516	CyDisCo production of functional recombinant SARS-CoV-2 spike receptor binding domain. <i>Protein Science</i> , 2021, 30, 1983-1990.	3.1	16
517	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	3.2	113
518	Origin and Impact of COVID-19 on Socioeconomic Status. , 0, , .		0
519	SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 607886.	1.6	11

#	ARTICLE	IF	CITATIONS
520	SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study. <i>Materials Today: Proceedings</i> , 2022, 49, 904-912.	0.9	14
521	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1349-1361.	2.5	3
522	Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody. <i>Journal of Physical Chemistry B</i> , 2021, 125, 7368-7379.	1.2	25
523	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <i>ACS Infectious Diseases</i> , 2021, 7, 2546-2564.	1.8	34
524	Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?. <i>Current Drug Targets</i> , 2021, 22, 1149-1157.	1.0	0
525	Sex-based clinical and immunological differences in COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 647.	1.3	33
526	Natural product remedies for COVID-19: A focus on safety. <i>South African Journal of Botany</i> , 2021, 139, 386-398.	1.2	32
527	Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket. <i>Journal of the American Chemical Society</i> , 2021, 143, 11349-11360.	6.6	54
529	SARS-CoV-2 infecting endothelial cells, biochemical alterations, autopsy findings and outcomes in COVID-19, suggest role of hypoxia-inducible factor-1. <i>Journal of Medical Biochemistry</i> , 2022, 41, 14-20.	0.7	3
531	A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. <i>Drugs in R and D</i> , 2021, 21, 273-283.	1.1	20
533	Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic. <i>Nanomaterials</i> , 2021, 11, 1841.	1.9	18
534	Temporal landscape of mutational frequencies in SARS-CoV-2 genomes of Bangladesh: possible implications from the ongoing outbreak in Bangladesh. <i>Virus Genes</i> , 2021, 57, 413-425.	0.7	7
535	Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, Mpro and PLpro of SARS-CoV-2: Protein-Protein Interactions, Dynamics Simulations and Free Energy Calculations. <i>Molecules</i> , 2021, 26, 5114.	1.7	11
536	Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats. <i>BMC Infectious Diseases</i> , 2021, 21, 871.	1.3	4
537	Structure-Based Virtual Screening and Molecular Dynamics Simulation to Identify Potential SARS-CoV-2 Spike Receptor Inhibitors from Natural Compound Database. <i>Pharmaceutical Chemistry Journal</i> , 2021, 55, 441-453.	0.3	3
539	Spike protein mutational landscape in India during the complete lockdown phase: Could Muller's ratchet be a future game-changer for COVID-19?. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104874.	1.0	1
540	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <i>Nature Microbiology</i> , 2021, 6, 1188-1198.	5.9	314
541	An unexpected biomaterial against SARS-CoV-2: Bio-polyphosphate blocks binding of the viral spike to the cell receptor. <i>Materials Today</i> , 2021, 51, 504-524.	8.3	8

#	ARTICLE	IF	CITATIONS
543	Genome-wide covariation in SARS-CoV-2. <i>Mathematical Biosciences</i> , 2021, 341, 108678.	0.9	2
544	Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 679841.	2.2	28
545	Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 1106-1119.	1.9	4
547	Antisense Peptide Technology for Diagnostic Tests and Bioengineering Research. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9106.	1.8	5
548	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
549	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
550	Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view. <i>Life Sciences</i> , 2021, 278, 119580.	2.0	5
551	Aspectos biofísicos de la transmisión del SARS-CoV-2 y medidas para contrarrestar la COVID-19: una revisión integral. <i>Duazary</i> , 2021, 18, 280-294.	0.0	0
552	Molecular docking and dynamic simulation of conserved B cell epitope of SARS-CoV-2 glycoprotein Indonesian isolates: an immunoinformatic approach. <i>F1000Research</i> , 2021, 10, 813.	0.8	7
554	Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant. <i>Biomolecules</i> , 2021, 11, 1244.	1.8	17
555	Angiotensin-converting enzyme type 2 and aldosterone synthesis: beyond the renin-angiotensin-aldosterone system and closer to the clinic. <i>Journal of Hypertension</i> , 2021, 39, 1546-1548.	0.3	0
556	Peptide Platform as a Powerful Tool in the Fight against COVID-19. <i>Viruses</i> , 2021, 13, 1667.	1.5	9
557	Binding Strength and Hydrogen Bond Numbers between COVID-19 RBD and HVR of Antibody. <i>Crystals</i> , 2021, 11, 997.	1.0	0
558	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	6
559	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
560	Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 71.	3.1	26
561	Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor. <i>Scientific Reports</i> , 2021, 11, 15650.	1.6	17
562	Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV. <i>Advanced Therapeutics</i> , 2021, 4, 2100104.	1.6	11

#	ARTICLE	IF	CITATIONS
564	Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Medical Research, 2021, 8, 47.	1.9	88
565	Molecular Dynamics Studies on the Structural Characteristics for the Stability Prediction of SARS-CoV-2. International Journal of Molecular Sciences, 2021, 22, 8714.	1.8	8
566	Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE, 2021, 16, e0255796.	1.1	3
567	Detection of Infectious Viruses Using CRISPR-Cas12-Based Assay. Biosensors, 2021, 11, 301.	2.3	27
568	Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. Viruses, 2021, 13, 1595.	1.5	23
569	Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Pharmaceuticals, 2021, 14, 805.	1.7	7
570	Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives. International Journal of Nanomedicine, 2021, Volume 16, 5713-5743.	3.3	26
571	Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chemical Engineering Journal, 2021, 418, 129392.	6.6	53
572	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Scientific Reports, 2021, 11, 17642.	1.6	41
573	The Long-Term Characteristics of Immunity Conferred by COVID-19 Using Antibody Tests. Cureus, 2021, 13, e17731.	0.2	1
575	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. Frontiers in Immunology, 2021, 12, 707977.	2.2	21
576	Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibility. Clinical Immunology, 2021, 230, 108824.	1.4	5
577	Tracking the interaction between single-wall carbon nanotube and SARS-Cov-2 spike glycoprotein: A molecular dynamics simulations study. Computers in Biology and Medicine, 2021, 136, 104692.	3.9	28
578	Untargeted Metabolic Profiling of Extracellular Vesicles of SARS-CoV-2-Infected Patients Shows Presence of Potent Anti-Inflammatory Metabolites. International Journal of Molecular Sciences, 2021, 22, 10467.	1.8	16
579	Evaluation of Photobiogoverning Role of Blue Light Irradiation on Viral Replication. Photochemistry and Photobiology, 2022, 98, 461-470.	1.3	4
580	Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). Journal of Virus Eradication, 2021, 7, 100054.	0.3	67
581	In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2. Molecules, 2021, 26, 5724.	1.7	39
582	Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay. Journal of Traditional and Complementary Medicine, 2022, 12, 73-89.	1.5	16

#	ARTICLE	IF	CITATIONS
583	Fast, accurate, point-of-care COVID-19 pandemic diagnosis enabled through advanced lab-on-chip optical biosensors: Opportunities and challenges. <i>Applied Physics Reviews</i> , 2021, 8, 031313.	5.5	61
584	Diagnosis and Possible Use of Traditional Medicinal Plant to combat COVID-19. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
585	Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 739-749.	1.5	151
587	Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. <i>ACS Omega</i> , 2021, 6, 26354-26371.	1.6	11
588	Neutralizing antibodies for the prevention and treatment of COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2293-2306.	4.8	91
589	The Complex Interplay between Immunonutrition, Mast Cells, and Histamine Signaling in COVID-19. <i>Nutrients</i> , 2021, 13, 3458.	1.7	7
590	Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2. <i>Computers in Biology and Medicine</i> , 2021, 136, 104719.	3.9	4
591	Emerging Pulmonary Infections in Clinical Practice. <i>Advances in Clinical Radiology</i> , 2021, 3, 103-124.	0.1	0
592	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. <i>Cell Discovery</i> , 2021, 7, 82.	3.1	22
593	In silico identification of RBD subdomain of spike protein from Pro322-Thr581 for applications in vaccine development against SARS-CoV2. <i>Journal of Molecular Structure</i> , 2021, 1240, 130534.	1.8	2
594	Rapid Detection of SARS-CoV-2 Antigens and Antibodies Using OFET Biosensors Based on a Soft and Stretchable Semiconducting Polymer. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 2140-2147.	2.6	32
595	Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. <i>PLoS ONE</i> , 2021, 16, e0249254.	1.1	31
596	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
597	SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms. <i>Molecular Systems Biology</i> , 2021, 17, e10079.	3.2	22
598	Severe Acute Respiratory Syndrome Coronavirus 2: The Role of the Main Components of the Innate Immune System. <i>Inflammation</i> , 2021, 44, 2151-2169.	1.7	11
599	TRINITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2: ORIGIN, GENOTYPE, PHENOTYPE, AND IMMUNE RESPONSE IN CORONAVIRUS DISEASE-2019. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 28-36.	0.3	1
600	Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 735-757.	2.7	21
601	Structural Understanding of SARS-CoV-2 Drug Targets, Active Site Contour Map Analysis and COVID-19 Therapeutics. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	4

#	ARTICLE	IF	CITATIONS
602	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
603	Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. <i>Biomaterials</i> , 2021, 278, 121159.	5.7	23
604	Immunomodulation and immunotherapeutics of COVID-19. <i>Clinical Immunology</i> , 2021, 231, 108842.	1.4	7
605	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003769.	3.9	83
606	Paper-based analytical devices for virus detection: Recent strategies for current and future pandemics. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 144, 116424.	5.8	44
607	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
608	Computational modeling of protein conformational changes - Application to the opening SARS-CoV-2 spike. <i>Journal of Computational Physics</i> , 2021, 444, 110591.	1.9	6
609	Resurgence of phosphotyrosine binding domains: Structural and functional properties essential for understanding disease pathogenesis. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129977.	1.1	3
610	Perspectives on electrochemical biosensing of COVID-19. <i>Current Opinion in Electrochemistry</i> , 2021, 30, 100794.	2.5	19
611	SARS-CoV-2 concentrations in a wastewater collection system indicated potential COVID-19 hotspots at the zip code level. <i>Science of the Total Environment</i> , 2021, 800, 149480.	3.9	22
612	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166264.	1.8	5
613	Spread of COVID-19 and Its Main Modes of Transmission. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 78-95.	0.1	0
615	COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	14
617	Predicting Genotype Information Related to COVID-19 for Molecular Mechanism Based on Computational Methods. <i>CMES - Computer Modeling in Engineering and Sciences</i> , 2021, 129, 31-45.	0.8	2
618	Possible role of traditional systems of medicine to manage covid-19: A review. <i>Israel Journal of Plant Sciences</i> , 2021, 68, 1-26.	0.3	8
619	Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin. <i>Molecules</i> , 2021, 26, 406.	1.7	35
620	Receptor-binding domain of SARS-CoV-2 spike protein efficiently inhibits SARS-CoV-2 infection and attachment to mouse lung. <i>International Journal of Biological Sciences</i> , 2021, 17, 3786-3794.	2.6	9
621	Principles and Challenges in anti-COVID-19 Vaccine Development. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 339-349.	0.9	38

#	ARTICLE	IF	CITATIONS
622	Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors. <i>Scientific Reports</i> , 2021, 11, 1156.	1.6	6
623	Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 575-604.	0.8	0
624	T cell epitopes of SARS-CoV-2 spike protein and conserved surface protein of <i>Plasmodium malariae</i> share sequence homology. <i>Open Life Sciences</i> , 2021, 16, 630-640.	0.6	4
625	What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. <i>Journal of Korean Medical Science</i> , 2021, 36, e54.	1.1	24
626	SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. <i>PLoS Pathogens</i> , 2021, 17, e1009233.	2.1	162
627	Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches. <i>Journal of Physical Chemistry B</i> , 2021, 125, 850-873.	1.2	66
628	Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
629	Insights into Pathology and Pathogenesis of Coronavirus Disease 2019 from a Histopathological and Immunological Perspective. <i>JMA Journal</i> , 2021, 4, 179-186.	0.6	5
630	Applications of Artificial Intelligence and Molecular Immune Pathogenesis, Ongoing Diagnosis and Treatments for COVID-19. <i>Studies in Systems, Decision and Control</i> , 2021, , 521-549.	0.8	0
632	Molecular modeling of natural and synthesized inhibitors against SARS-CoV-2 spike glycoprotein. <i>Research on Biomedical Engineering</i> , 0, , 1.	1.5	2
633	COVID-19 and the Microbiome: The Gut-Lung Connection. , 2022, , 442-458.		4
634	Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. <i>Vaccines</i> , 2021, 9, 76.	2.1	28
635	Acute Kidney Injury in Hospitalized Patients Infected with COVID-19 from Wuhan, China: A Retrospective Study. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	10
638	siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID-19 Therapies?. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001650.	3.9	47
639	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	1.2	60
640	Methylene Blue Inhibits the SARS-CoV-2 Spike—ACE2 Protein-Protein Interaction—a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 600372.	1.6	64
641	Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. <i>Small Methods</i> , 2021, 5, 2001031.	4.6	25
642	Emergence and Reemergence of Severe Acute Respiratory Syndrome (SARS) Coronaviruses. <i>Medical Virology</i> , 2020, , 151-163.	2.1	5

#	ARTICLE	IF	CITATIONS
643	SARS-CoV-2 and diabetes: New challenges for the disease. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108228.	1.1	48
644	In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19. <i>Scientific Reports</i> , 2020, 10, 22387.	1.6	38
645	A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. <i>Bioscience Reports</i> , 2020, 40, .	1.1	82
646	Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs. <i>Clinical Science</i> , 2020, 134, 1143-1150.	1.8	23
647	Progress in understanding COVID-19: insights from the omics approach. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 242-252.	2.7	13
648	Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach. <i>Briefings in Bioinformatics</i> , 2021, 22, 1346-1360.	3.2	62
649	The Impact of SARS-CoV-2 on the Human Immune System and Microbiome. <i>Infectious Microbes & Diseases</i> , 2021, 3, 14-21.	0.5	11
650	SARS-CoV-2 receptor ACE2 and molecular pathway to enter target cells during infection. <i>Reviews in Medical Microbiology</i> , 2022, 33, e105-e113.	0.4	6
725	Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 853-865.	2.7	34
726	Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2. <i>Bulletin of the National Research Centre</i> , 2020, 44, 193.	0.7	7
727	A promising vaccine candidate against COVID-19. <i>Molecular Biomedicine</i> , 2020, 1, 8.	1.7	3
728	Analyses of spike protein from first deposited sequences of SARS-CoV2 from West Bengal, India. <i>F1000Research</i> , 2020, 9, 371.	0.8	10
729	Immunopathology of galectin-3: an increasingly promising target in COVID-19. <i>F1000Research</i> , 2020, 9, 1078.	0.8	23
730	Immunopathology of galectin-3: an increasingly promising target in COVID-19. <i>F1000Research</i> , 2020, 9, 1078.	0.8	59
731	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. <i>PLoS Biology</i> , 2020, 18, e3001016.	2.6	169
732	Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: A molecular docking and simulation studies. <i>PLoS ONE</i> , 2020, 15, e0240653.	1.1	115
734	COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?. <i>Aging</i> , 2020, 12, 6511-6517.	1.4	170
735	Molecular Review Covid19 from the Pathogenesis and Transmission Aspect. <i>Jurnal Kesehatan Lingkungan</i> , 2020, 12, 93.	0.1	1

#	ARTICLE	IF	CITATIONS
736	COVID-19 and Liver Damage. Russian Archives of Internal Medicine, 2020, 10, 188-197.	0.0	15
739	SARS-CoV-2 (COVID-19): Zoonotic Origin and Susceptibility of Domestic and Wild Animals. Journal of Pure and Applied Microbiology, 2020, 14, 741-747.	0.3	12
740	Molecular Characterization and Amino Acid Homology of Nucleocapsid (N) Protein in SARS-CoV-1, SARS-CoV-2, MERS-CoV, and Bat Coronavirus. Journal of Pure and Applied Microbiology, 2020, 14, 757-763.	0.3	10
743	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. Electronic Journal of General Medicine, 2020, 17, em251.	0.3	12
744	Seasonal variations in Nigeria: understanding COVID-19 transmission dynamics and immune responses. Journal of Global Health Reports, 0, 4, .	1.0	4
745	COVID-19 and the gastrointestinal tract: what do we already know?. Einstein (Sao Paulo, Brazil), 2020, 18, eRW5909.	0.3	17
746	The Rise and Impact of COVID-19 in India. Frontiers in Medicine, 2020, 7, 250.	1.2	100
747	The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. Frontiers in Physiology, 2021, 12, 627260.	1.3	32
748	A Guide to the Short, Long and Circular RNAs in Hypertension and Cardiovascular Disease. International Journal of Molecular Sciences, 2020, 21, 3666.	1.8	16
749	Markers Associated with COVID-19 Susceptibility, Resistance, and Severity. Viruses, 2021, 13, 45.	1.5	30
750	SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN- β Production. Viruses, 2021, 13, 47.	1.5	114
751	Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community. Research, 2020, 2020, 6925296.	2.8	26
752	A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines. BioImpacts, 2021, 11, 65-84.	0.7	39
753	Pathogen Genomics and Host Cellular Susceptibility Factors of COVID-19. Global Clinical and Translational Research, 2020, , 107-126.	0.4	4
754	PHARMACOTHERAPY of COVID-19. Veteriner Farmakoloji Ve Toksikoloji Derneği Bülteni, 2020, 11, 80-114.	0.1	4
755	Clinical characteristics and infectivity of asymptomatic carriers of SARS-CoV-2 (Review). Experimental and Therapeutic Medicine, 2020, 21, 115.	0.8	9
756	Current laboratory diagnosis of coronavirus disease 2019. Korean Journal of Internal Medicine, 2020, 35, 741-748.	0.7	20
757	Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and treatment. AIMS Microbiology, 2020, 7, 183-203.	1.0	6

#	ARTICLE	IF	CITATIONS
758	COVID-19 Compared to Other Pandemic Diseases. Rambam Maimonides Medical Journal, 2020, 11, e0027.	0.4	60
759	ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. ELife, 2020, 9, .	2.8	266
760	Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. ELife, 2020, 9, .	2.8	165
761	Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. Drugs in Context, 2020, 9, 1-14.	1.0	14
762	Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: an in silico approach. PeerJ, 2020, 8, e9572.	0.9	108
763	Potential Zoonotic Origins of SARS-CoV-2 and Insights for Preventing Future Pandemics Through One Health Approach. Cureus, 2020, 12, e8932.	0.2	31
764	The renin-angiotensin system – a therapeutic target in COVID-19?. Clinical Medicine, 2020, 20, e72-e75.	0.8	20
765	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients. Journal of Pharmaceutical Research International, 0, , 13-25.	1.0	7
766	Computational anti-COVID-19 drug design: progress and challenges. Briefings in Bioinformatics, 2022, 23, .	3.2	8
767	The Recent Updates on Approaches and Clinical Trials Status of Covid-19 Vaccines Developed Globally. Biomedical and Pharmacology Journal, 2021, 14, 1109-1124.	0.2	9
768	Exosomes: Emerging implementation of nanotechnology for detecting and managing novel corona virus- SARS-CoV-2. Asian Journal of Pharmaceutical Sciences, 2022, 17, 20-34.	4.3	10
769	Effectiveness of COVID-19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 2021, 22, 1407.	0.8	23
770	A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens. Advanced Healthcare Materials, 2021, 10, e2101370.	3.9	10
771	Cell Entry of Animal Coronaviruses. Viruses, 2021, 13, 1977.	1.5	12
772	Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound. Food Science and Nutrition, 2021, 9, 6513-6523.	1.5	8
773	SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray. Scientific Reports, 2021, 11, 20012.	1.6	31
775	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. FASEB Journal, 2021, 35, e21970.	0.2	22
776	Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. GeroScience, 2021, 43, 2289-2304.	2.1	13

#	ARTICLE	IF	CITATIONS
777	Distant residues modulate conformational opening in SARS-CoV-2 spike protein. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	69
778	Severe acute respiratory syndrome-coronavirus 2 in domesticated animals and its potential of transmission: A meta-analysis. Veterinary World, 2021, 14, 2782-2792.	0.7	3
779	Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. Journal of Travel Medicine, 2021, 28, .	1.4	24
780	ACE2: a key modulator of the renin-angiotensin system and pregnancy. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 321, R833-R843.	0.9	18
781	In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine. Molecules, 2021, 26, 6182.	1.7	23
782	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. International Journal of Biological Macromolecules, 2021, , .	3.6	14
783	Applications of Charge Detection Mass Spectrometry in Molecular Biology and Biotechnology. Chemical Reviews, 2022, 122, 7415-7441.	23.0	45
784	SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19. Metabolism Open, 2021, 12, 100134.	1.4	6
787	Exploring pathophysiology of COVID-19 infection: Faux espoir and dormant therapeutic options. International Journal of Clinical Virology, 2020, 4, 034-040.	0.1	1
788	COVID-19 Pandemic: Emerging Issues and Future Challenges. , 0, 1, 1.		0
794	COVID-19: A Centennial Pandemic from Origin to Clinical Trials. Acta Biologica Marisiensis, 2020, 3, 30-52.	0.1	1
798	Receptor enzima convertidora de angiotensina y correlaci3n con COVID-19 ¿Que conocemos hasta el momento?. Revista Colombiana De NefrologÃa, 2020, 7, 31-32.	0.1	0
803	Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker. Journal of Applied Microbiology, 2022, 132, 2421-2430.	1.4	18
804	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. Journal of Molecular Biology, 2022, 434, 167332.	2.0	22
805	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. International Journal of Biological Macromolecules, 2021, 193, 1249-1273.	3.6	19
806	Liver injury in COVID-19: two clinical cases. AlE1manah KliniÃeskoj Mediciny, 2020, 48, 412-421.	0.2	4
807	Is The SARS-CoV2 evolved in Human Being: A prospective Genetic Analysis. Kurdistan Journal of Applied Research, 0, , 169-177.	0.4	0
810	Modern vaccines and coronavirus infections. IssledovaniÃc I Praktika V Medicine, 2020, 7, 135-154.	0.1	2

#	ARTICLE	IF	CITATIONS
811	Analysis and Prediction of COVID-19 Timeline and Infection Rates. , 2020, , .		0
813	Design of Multi-Epitope Vaccine against SARS-CoV-2. Cybernetics and Information Technologies, 2020, 20, 185-193.	0.4	0
814	Development of an enzyme-linked immunosorbent assay for the detection of IgG-antibodies to the causative agent of COVID-19 in human serum (plasma). Klinicheskaya Laboratornaya Diagnostika, 2020, 65, 683-687.	0.2	3
816	Mechanistic insights into the effects of key mutations on SARS-CoV-2 RBD-ACE2 binding. Physical Chemistry Chemical Physics, 2021, 23, 26451-26458.	1.3	19
817	Carbon nanotube field-effect transistor (CNT-FET)-based biosensor for rapid detection of SARS-CoV-2 (COVID-19) surface spike protein S1. Bioelectrochemistry, 2022, 143, 107982.	2.4	117
818	Electrochemical sensors for the detection of SARS-CoV-2 virus. Chemical Engineering Journal, 2022, 430, 132966.	6.6	115
819	Tropical Food Spices: A Promising Panacea for the Novel Coronavirus Disease (COVID-19). EFood, 2020, 1, 347.	1.7	9
820	Exploring the Mediation Effect of Awareness and Quarantine in Affecting Rate: A Study on COVID-19. SSRN Electronic Journal, 2020, , 3624017.	0.4	0
821	Unbiased Local Sequencing Similarity Analysis for SARS-CoV-2 Worldwide. SSRN Electronic Journal, 0, , .	0.4	0
823	OUP accepted manuscript. CKJ: Clinical Kidney Journal, 2020, 13, 291-296.	1.4	20
824	COVID-19: Review on Its Etiology, Pathogenesis, and Existence in Humans. Biocell, 2020, 44, 461-467.	0.4	1
825	Development of an Inactivated Vaccine against SARS CoV-2. Vaccines, 2021, 9, 1266.	2.1	23
826	Emerging Biosensors to Detect Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Review. Biosensors, 2021, 11, 434.	2.3	40
833	Case Report: Unusual presentation of concomitant gastric outlet obstruction and jaundice complicating giant hepatic angioma. F1000Research, 0, 9, 1355.	0.8	0
834	Il laboratorio diagnostico e COVID-19: È possibile stabilire una strategia per la diagnosi dell'infezione da SARS-CoV-2 attraverso l'uso combinato di test molecolari e sierologici?. Rivista Italiana Della Medicina Di Laboratorio, 2020, 16, .	0.2	0
835	Analysing and Interpreting the Concept and Possible Implementation of Herd Immunity in the Human Population against COVID 19 Infections. , 2020, 1, 172-181.		1
837	Coronavirus disease-19 spread in the Eastern Mediterranean Region, updates and prediction of disease progression in Kingdom of Saudi Arabia, Iran, and Pakistan. International Journal of Health Sciences, 2020, 14, 32-42.	0.4	3
838	Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An approach. Indian Journal of Medical Research, 2021, 153, 132-143.	0.4	0

#	ARTICLE	IF	CITATIONS
839	Possible health benefits of polyphenols in neurological disorders associated with COVID-19. <i>Acta Facultatis Medicae Naissensis</i> , 2021, 38, 193-209.	0.1	3
840	Coronavirus infection outbreak. , 2022, , 47-57.		2
841	SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines. , 2022, , 213-229.		5
842	Designing a Multi-epitope Peptide Vaccine Against COVID-19 Variants Utilizing In-silico Tools. <i>Iranian Journal of Medical Microbiology</i> , 2021, 15, 592-605.	0.1	4
843	Recognizing Significant Motifs of Corona Virus Spike Proteins using Computational Approaches. , 2021, , .		1
845	Cardiovascular complications after COVID-19 in chronic kidney disease, dialysis and kidney transplant patients. <i>International Urology and Nephrology</i> , 2022, 54, 1551-1563.	0.6	5
846	COVID-19 Pandemic Effect on Energy Consumption in State Universities: Michoacan, Mexico Case Study. <i>Energies</i> , 2021, 14, 7642.	1.6	8
848	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme ² , Mutual Effects and Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 772865.	1.5	15
849	Fabrication of a sensitive sensor for determination of xanthine in the presence of uric acid and ascorbic acid by modifying a carbon paste sensor with Fe ₃ O ₄ @Au core-shell and an ionic liquid. <i>Journal of Food Measurement and Characterization</i> , 2022, 16, 731-739.	1.6	14
850	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
851	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. <i>Viruses</i> , 2021, 13, 2295.	1.5	13
852	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
853	Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor. <i>Scientific Reports</i> , 2021, 11, 22202.	1.6	5
854	Ginger from Farmyard to Town: Nutritional and Pharmacological Applications. <i>Frontiers in Pharmacology</i> , 2021, 12, 779352.	1.6	36
855	Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae <i>Chlamydomonas reinhardtii</i> . <i>PLoS ONE</i> , 2021, 16, e0257089.	1.1	20
857	Advances in mRNA and other vaccines against MERS-CoV. <i>Translational Research</i> , 2022, 242, 20-37.	2.2	11
858	Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle. <i>Vaccines</i> , 2021, 9, 1347.	2.1	37
859	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. <i>PLoS ONE</i> , 2021, 16, e0260283.	1.1	1

#	ARTICLE	IF	CITATIONS
861	Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12638.	1.8	45
862	Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice. <i>Science Advances</i> , 2021, 7, eabj1476.	4.7	27
863	Role of Flavonoids against COVID-19. <i>The Open Biology Journal</i> , 2021, 9, 47-55.	0.5	0
865	The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression. <i>Biomolecules</i> , 2021, 11, 1812.	1.8	22
866	Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach. <i>Indian Journal of Medical Research</i> , 2021, 153, 132.	0.4	10
867	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110630.	1.1	7
869	Neurological disorders seen during second wave of SARS-CoV-2 pandemic from two tertiary care centers in central and Southern Kerala. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 917.	0.2	6
870	“But Mouse, You Are Not Alone” On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting Mice. <i>ILAR Journal</i> , 2021, 62, 48-59.	1.8	10
871	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22
872	SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody. <i>Computers in Biology and Medicine</i> , 2022, 142, 105226.	3.9	26
873	Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection. <i>IScience</i> , 2022, 25, 103684.	1.9	3
874	Development and validation of novel kit for quantification of SARS-CoV-2 antibodies on clinical samples. <i>Journal of Virological Methods</i> , 2022, 300, 114423.	1.0	1
875	Kerja Harmoni Zat Gizi dalam Meningkatkan Imunitas Tubuh Terhadap Covid-19: Mini Review. <i>Amerta Nutrition</i> , 2020, 4, 250.	0.1	6
876	Dengue Lurks During Coronavirus Disease-19 Pandemic in Indonesia: A Narrative Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 391-398.	0.1	2
878	The Importance of Glycosylation in COVID-19 Infection. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1325, 239-264.	0.8	9
879	Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 225-233.	0.2	0
881	Damage to the Vascular Endothelium as a Leading Mechanism of COVID-19 Systemic Pathology. <i>Biology Bulletin Reviews</i> , 2021, 11, 559-566.	0.3	3
883	SARS-CoV-2 “host cell surface interactions and potential antiviral therapies. <i>Interface Focus</i> , 2022, 12, 20200081.	1.5	4

#	ARTICLE	IF	CITATIONS
884	Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants: Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1646.	1.8	2
885	Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?. <i>Molecular Neurobiology</i> , 2022, 59, 1850-1861.	1.9	76
886	Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	54
887	Structure- and Interaction- Based Design of Anti-SARS-CoV-2 Aptamers. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	9
888	Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 275-379.	1.0	7
889	Potential Genes Associated with COVID-19 and Comorbidity. <i>International Journal of Medical Sciences</i> , 2022, 19, 402-415.	1.1	26
891	Can Nutritional Supports Beneficial in Other Viral Diseases Be Favorable for COVID-19?. <i>Korean Journal of Family Medicine</i> , 2022, 43, 3-15.	0.4	1
892	Computational Insights into the Allosteric Effect and Dynamic Structural Features of the SARS-CoV-2 Spike Protein. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	9
893	Hypozincemia in COVID-19 Patients Correlates With Stronger Antibody Response. <i>Frontiers in Immunology</i> , 2021, 12, 785599.	2.2	4
894	Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2. <i>Microorganisms</i> , 2022, 10, 280.	1.6	25
895	Secondary Structures of the Transmembrane Domain of SARS-CoV-2 Spike Protein in Detergent Micelles. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1040.	1.8	4
896	Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring. <i>Clinical Immunology</i> , 2022, 234, 108918.	1.4	15
897	Pre-SARS-CoV-2 Human Sera Reacts with Peptides from All the 7 Human Coronaviruses: Peptide Microarray IgM and IgG Screening. <i>SSRN Electronic Journal</i> , 0, .	0.4	0
899	Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2. <i>Scientific Reports</i> , 2022, 12, 692.	1.6	9
900	Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. <i>Vaccines</i> , 2022, 10, 96.	2.1	23
901	Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development. <i>Molecules</i> , 2022, 27, 536.	1.7	39
902	Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. <i>Journal of Natural Products</i> , 2022, 85, 176-184.	1.5	75
903	Excavating phytochemicals from plants possessing antiviral activities for identifying SARS-CoV hemagglutinin-esterase inhibitors by diligent computational workflow. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2382-2397.	2.0	5

#	ARTICLE	IF	CITATIONS
904	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
905	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 37.	0.9	2
907	Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine. <i>PLoS Pathogens</i> , 2022, 18, e1009903.	2.1	1
908	Mechanisms contributing to adverse outcomes of COVID-19 in obesity. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 1155-1193.	1.4	21
909	A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in <i>E. coli</i> Using a SEP-Tag Produces Antisera Interacting with the Mammalian Cell Expressed Spike (S1) Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1703.	1.8	15
910	Active site-based analysis of structural proteins for drug targets in different human <i>Coronaviruses</i> . <i>Chemical Biology and Drug Design</i> , 2022, 99, 585-602.	1.5	4
911	HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19. <i>IScience</i> , 2022, 25, 103856.	1.9	23
912	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
913	Detection and discrimination of SARS-CoV-2 spike protein-derived peptides using THz metamaterials. <i>Biosensors and Bioelectronics</i> , 2022, 202, 113981.	5.3	27
915	A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac017.	0.1	15
917	Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. <i>Molecular Diversity</i> , 2022, 26, 3309-3324.	2.1	17
918	Long COVID, neuropsychiatric disorders, psychotropics, present and future. <i>Acta Neuropsychiatrica</i> , 2022, 34, 109-126.	1.0	30
919	Multifarious global flora fabricated phytosynthesis of silver nanoparticles: a green nanoweapon for antiviral approach including SARS-CoV-2. <i>International Nano Letters</i> , 2022, 12, 313-344.	2.3	6
920	Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6574-6585.	2.5	9
921	The dynamic nature of the coronavirus receptor, angiotensin-converting enzyme 2 (ACE2) in differentiating airway epithelia. <i>BBA Advances</i> , 2022, 2, 100044.	0.7	2
923	Rapid characterization of spike variants via mammalian cell surface display. <i>Molecular Cell</i> , 2021, 81, 5099-5111.e8.	4.5	32
924	Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 11850-11857.	2.1	73
925	A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation. <i>Scientific Reports</i> , 2021, 11, 24507.	1.6	7

#	ARTICLE	IF	CITATIONS
928	Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning. <i>Protein Engineering, Design and Selection</i> , 2022, 35, .	1.0	8
929	COVID-19: Immune response. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 467-470.	0.2	8
930	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 41-58.	1.9	26
931	Evaluation of Peppermint Leaf Flavonoids as SARS-CoV-2 Spike Receptor-Binding Domain Attachment Inhibitors to the Human ACE2 Receptor: A Molecular Docking Study. <i>Open Journal of Biophysics</i> , 2022, 12, 132-152.	0.7	3
933	Targeting Angiotensin-Converting Enzyme 2 (ACE2) for the Discovery of Anticoronaviral Drugs. <i>Coronaviruses</i> , 2022, 03, .	0.2	0
935	Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2172.	1.8	5
936	Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2928.	1.8	8
938	Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants. <i>JCI Insight</i> , 2022, 7, .	2.3	10
939	Investigation of the effect of wall geometry change on thermal resistance, temperature uniformity and FOM of a micro-heat sink containing nanofluid flow. <i>European Physical Journal Plus</i> , 2022, 137, 1.	1.2	1
940	Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and <i>Streptococcus pneumoniae</i> . <i>Advanced Materials</i> , 2022, 34, e2200443.	11.1	11
941	Use of Circular Dichroism in the characterization of the fusion protein SARS-CoV-2 RBD-hFc. <i>Pure and Applied Chemistry</i> , 2022, 94, 829-838.	0.9	0
942	Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 797132.	1.6	3
943	Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 799703.	1.6	11
944	A rapid bead-based assay for screening of SARS-CoV-2 neutralizing antibodies. <i>Antibody Therapeutics</i> , 2022, 5, 100-110.	1.2	3
945	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments. <i>Therapeutic Delivery</i> , 2022, 13, 187-203.	1.2	8
946	The evolution of SARS-CoV-2 variants and their clinical and healthcare implications. <i>Revista Cl&#x00e9;nica Espan&#x00f5;la</i> , 2022, , .	0.3	1
947	Rapid and Quantitative <i>In Vitro</i> Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies. <i>Analytical Chemistry</i> , 2022, 94, 4504-4512.	3.2	3
948	Various vaccine platforms in the field of COVID-19. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, 35.	0.8	10

#	ARTICLE	IF	CITATIONS
949	Tryptophan capped gold-aryl nanoparticles for energy transfer study with SARS-CoV-2 spike proteins. <i>Soft Materials</i> , 2022, 20, 405-413.	0.8	4
950	Methylxanthines as Potential Inhibitor of SARS-CoV-2: an In Silico Approach. <i>Current Pharmacology Reports</i> , 2022, 8, 149-170.	1.5	15
951	Nematicidal Property of Clindamycin and 5-hydroxy-2-methyl Furfural (HMF) from the Banana Endophyte <i>Bacillus velezensis</i> (YE666) Against Banana Burrowing Nematode <i>Radopholus similis</i> . <i>Indian Journal of Microbiology</i> , 2022, 62, 364-373.	1.5	4
952	<i>In silico</i> design of ACE2 mutants for competitive binding of SARS-CoV-2 receptor binding domain with hACE2. <i>ChemistrySelect</i> , 2022, .	0.7	0
953	Reduced COVID-19 mortality linked with early antibodies against SARS-CoV-2, irrespective of age. <i>European Journal of Internal Medicine</i> , 2022, 98, 77-82.	1.0	7
954	Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids. <i>Cells</i> , 2022, 11, 1235.	1.8	21
955	Prefusion spike protein conformational changes are slower in SARS-CoV-2 than in SARS-CoV-1. <i>Journal of Biological Chemistry</i> , 2022, 298, 101814.	1.6	17
956	COVID-19: Cellular and Molecular Mechanisms of Brain Damage. <i>Biology Bulletin Reviews</i> , 2022, 12, 131-139.	0.3	0
957	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. <i>Antiviral Research</i> , 2022, 200, 105290.	1.9	3
958	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. <i>MAbs</i> , 2022, 14, 2057832.	2.6	7
959	Recycling rice straw ash to produce low thermal conductivity and moisture-resistant geopolymer adobe bricks. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 3759-3771.	1.8	15
960	Synthesis, spectroscopic characterization of novel phthalimides derivatives bearing a 1,2,3-triazole unit and examination as potential SARS-CoV-2 inhibitors via in silico studies. <i>Journal of Molecular Structure</i> , 2022, 1261, 132915.	1.8	8
962	Epidemic Preparednessâ€” <i>Leishmania tarentolae</i> as an Easy-to-Handle Tool to Produce Antigens for Viral Diagnosis: Application to COVID-19. <i>Frontiers in Microbiology</i> , 2021, 12, 736530.	1.5	7
963	Naringenin as a Possible Candidate Against SARS-CoV-2 Infection and in the Pathogenesis of COVID-19. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110667.	0.2	11
964	Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In <i>Nicotiana benthamiana</i> Plant With Potent Anti-SARS-CoV-2 Activity. <i>Frontiers in Plant Science</i> , 2021, 12, 742875.	1.7	11
965	Curcumin Analogues as a Potential Drug against Antibiotic Resistant Protein, Î²-Lactamases and L, D-Transpeptidases Involved in Toxin Secretion in <i>Salmonella typhi</i> : A Computational Approach. <i>BioMedInformatics</i> , 2022, 2, 77-100.	1.0	3
966	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
969	Potential COVID-19 therapeutic approaches targeting angiotensinâ€”converting enzyme 2; An updated review. <i>Reviews in Medical Virology</i> , 2022, 32, e2321.	3.9	16

#	ARTICLE	IF	CITATIONS
971	Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen. ACS Omega, 2021, 6, 35657-35666.	1.6	27
972	Highly Sensitive and Specific SARS-CoV-2 Serological Assay Using a Magnetic Modulation Biosensing System. Biosensors, 2022, 12, 7.	2.3	3
973	IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution. Frontiers in Medicine, 2021, 8, 765249.	1.2	5
974	Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. Science Advances, 2021, 7, eabj6538.	4.7	19
975	A Recent Update on Advanced Molecular Diagnostic Techniques for COVID-19 Pandemic: An Overview. Frontiers in Immunology, 2021, 12, 732756.	2.2	49
976	Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2. PLoS Biology, 2021, 19, e3001510.	2.6	7
977	The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence. Frontiers in Pharmacology, 2021, 12, 731453.	1.6	27
978	COVID-19: The question of genetic diversity and therapeutic intervention approaches. Genetics and Molecular Biology, 2021, 44, e20200452.	0.6	1
979	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. Cell Transplantation, 2022, 31, 096368972210902.	1.2	3
980	Recent and advanced nano-technological strategies for COVID-19 vaccine development. Methods in Microbiology, 2022, , .	0.4	0
982	Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. International Journal of Molecular Sciences, 2022, 23, 4376.	1.8	16
983	Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2. Viruses, 2022, 14, 816.	1.5	3
984	COVID-19 Vaccines: Current and Future Perspectives. Vaccines, 2022, 10, 608.	2.1	26
985	Annotating Spike Protein Polymorphic Amino Acids of Variants of SARS-CoV-2, Including Omicron. Biochemistry Research International, 2022, 2022, 1-7.	1.5	3
986	Insect cell expression and purification of recombinant SARS-CoV-2 spike proteins that demonstrate ACE2 binding. Protein Science, 2022, 31, e4300.	3.1	5
987	Nanomaterials and metal-organic frameworks for biosensing applications of mutations of the emerging viruses. Analytical Biochemistry, 2022, 648, 114680.	1.1	11
988	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. Process Biochemistry, 2022, 118, 154-170.	1.8	4
989	Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Serological Diagnostic Tests and Antibody Kinetics in Coronavirus Disease 2019 Patients. Frontiers in Microbiology, 2022, 13, 881038.	1.5	2

#	ARTICLE	IF	CITATIONS
990	Electrochemical Sensor for Detection of Mifepristone and Cinnamic acid for Treatment of Uterine Fibroids using Immobilized Double-Stranded DNA on the AuNPs modified glassy carbon electrode. International Journal of Electrochemical Science, 0, , ArticleID:220564.	0.5	0
1006	Oral Immunization of Mice with Cell Extracts from Recombinant Lactococcus lactis Expressing SARS-CoV-2 Spike Protein. Current Microbiology, 2022, 79, 167.	1.0	6
1007	Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. International Journal of Biological Macromolecules, 2022, 209, 1359-1367.	3.6	3
1008	Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies. Computational and Structural Biotechnology Journal, 2022, 20, 2212-2222.	1.9	4
1009	Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. Frontiers in Immunology, 2022, 13, 856033.	2.2	5
1010	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. Pathogens, 2022, 11, 516.	1.2	10
1011	Phosphate-regulated expression of the SARS-CoV-2 receptor-binding domain in the diatom Phaeodactylum tricornutum for pandemic diagnostics. Scientific Reports, 2022, 12, 7010.	1.6	10
1012	A COVID-19 Vaccine for Dogs Prevents Reverse Zoonosis. Vaccines, 2022, 10, 676.	2.1	6
1013	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Translational Research, 2022, 248, 11-21.	2.2	13
1014	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. Frontiers in Drug Discovery, 2022, 2, .	1.1	5
1015	Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant. Journal of Physical Chemistry Letters, 2022, 13, 3915-3921.	2.1	49
1016	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. Osong Public Health and Research Perspectives, 2022, 13, 84-100.	0.7	0
1017	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. International Journal of Molecular Sciences, 2022, 23, 4894.	1.8	17
1018	Recombinant Protein Technology in the Challenging Era of Coronaviruses. Processes, 2022, 10, 946.	1.3	3
1019	Hybrid drug-screening strategy identifies potential SARS-CoV-2 cell-entry inhibitors targeting human transmembrane serine protease. Structural Chemistry, 2022, 33, 1503-1515.	1.0	4
1020	Proteome Exploration of Human Coronaviruses for Identifying Novel Vaccine Candidate: A Hierarchical Subtractive Genomics and Reverse Vaccinology Approach. Recent Patents on Biotechnology, 2023, 17, 163-175.	0.4	1
1021	Sustainability analysis of a hybrid renewable power system with battery storage for islands application. Journal of Energy Storage, 2022, 50, 104682.	3.9	43
1022	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	2.2	6

#	ARTICLE	IF	CITATIONS
1023	In-stent Thrombosis and COVID-19 Infection: Current Insights on the Mechanistic Relationship. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	1
1024	COVID-19 in G6PD-deficient patients, oxidative stress, and neuropathology. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, .	1.0	3
1025	Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?. <i>Pharmaceuticals</i> , 2022, 15, 616.	1.7	7
1026	RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 43-53.	2.0	5
1027	Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies. <i>Chemical Science</i> , 2022, 13, 7224-7239.	3.7	6
1029	Whole-genome sequencing of SARS-CoV-2 reveals diverse mutations in circulating Alpha and Delta variants during the first, second, and third waves of COVID-19 in South Kivu, east of the Democratic Republic of the Congo. <i>International Journal of Infectious Diseases</i> , 2022, 122, 136-143.	1.5	14
1030	Receptor binding domain proteins of SARS-CoV-2 variants produced in <i>Nicotiana benthamiana</i> elicit neutralizing antibodies against variants of concern. <i>Journal of Medical Virology</i> , 2022, 94, 4265-4276.	2.5	10
1031	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. <i>Pharmaceutics</i> , 2022, 14, 1101.	2.0	15
1032	The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: a literature review. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	6
1033	mRNA-based therapeutics: powerful and versatile tools to combat diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	160
1035	Dietary guidelines to boost immunity during pre and post covid-19 conditions. <i>International Journal of Food Properties</i> , 2022, 25, 1246-1265.	1.3	1
1036	A Look inside the Replication Dynamics of SARS-CoV-2 in <i>Blyth's Horseshoe Bat (Rhinolophus Tj ETQq1 1 0,784314 rgBT /Over</i>	1.2	2
1037	Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	7
1038	Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7818-7832.	2.9	20
1039	Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
1040	Increased LAMP1 Expression Enhances SARS-CoV-1 and SARS-CoV-2 Production in Vero-Derived Transgenic Cell Lines. <i>Molecular Biology</i> , 2022, 56, 463-468.	0.4	2
1041	RNA enigma: From origin of life to novel Coronavirus- COVID-19. <i>Saudi Journal of Biological Sciences</i> , 2022, , 103331.	1.8	0
1042	Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	11

#	ARTICLE	IF	CITATIONS
1043	Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection. <i>Progress in Molecular and Subcellular Biology</i> , 2022, , 145-189.	0.9	4
1044	Antibody testing as the guide to our living with COVID-19. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 338-346.	0.1	0
1045	Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	7
1046	On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1047	Peptide mediated colorimetric detection of SARS-CoV-2 using gold nanoparticles: a molecular dynamics simulation study. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	2
1048	Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and Non-Dialysis CKD Patients with COVID-19â€”A Single Center Experience. <i>Journal of Personalized Medicine</i> , 2022, 12, 966.	1.1	2
1050	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
1051	Advancements in Testing Strategies for COVID-19. <i>Biosensors</i> , 2022, 12, 410.	2.3	8
1052	An updated review of <scp>SARSâ€CoV</scp>â€2 detection methods in the context of a novel coronavirus pandemic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	19
1053	Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants. , 2022, 19, 962-964.		4
1054	Heat transfer analysis of a water/lithium-bromide vapor generator system used for battery thermal development. <i>Journal of Energy Storage</i> , 2022, 53, 105118.	3.9	2
1055	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. , 2022, , 21-63.		0
1056	SARS, MERS, nSARS-CoV-2 infections and diseases: Emerging threats to public health. , 2022, , 235-252.		0
1057	Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	9
1058	Point-specific interactions of isovitexin with the neighboring amino acid residues of the hACE2 receptor as a targeted therapeutic agent in suppressing the SARS-CoV-2 influx mechanism. <i>Journal of Advanced Veterinary and Animal Research</i> , 2022, 9, 230.	0.5	21
1059	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
1060	SARS-CoV-2 cell entry beyond the ACE2 receptor. <i>Molecular Biology Reports</i> , 2022, 49, 10715-10727.	1.0	29
1061	Rapid self-test of unprocessed viruses of SARS-CoV-2 and its variants in saliva by portable wireless graphene biosensor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	32

#	ARTICLE	IF	CITATIONS
1062	Antibody–nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1063	COVID-19 Pathogen Viral Evolution Leading to Increased Infectivity. <i>Cureus</i> , 2022, , .	0.2	2
1064	Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 3018-3029.	1.0	6
1065	A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	63
1066	Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. <i>Biomolecules</i> , 2022, 12, 964.	1.8	0
1067	Psychiatric Manifestations of COVID-19: A Literature Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 892-905.	0.8	3
1068	Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry. <i>IScience</i> , 2022, 25, 104716.	1.9	6
1069	NMR Experiments Provide Insights into Ligand-Binding to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. <i>Journal of the American Chemical Society</i> , 2022, 144, 13060-13065.	6.6	7
1070	Investigation of potential inhibitor properties of violacein against HIV-1 RT and CoV-2 Spike RBD:ACE-2. <i>World Journal of Microbiology and Biotechnology</i> , 2022, 38, .	1.7	11
1071	TNF±-induced metabolic reprogramming drives an intrinsic anti-viral state. <i>PLoS Pathogens</i> , 2022, 18, e1010722.	2.1	2
1072	Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq. <i>Medical Immunology (Russia)</i> , 2022, 24, 729-740.	0.1	2
1073	A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. <i>Journal of Virology</i> , 2022, 96, .	1.5	7
1074	The beneficial role of Hepcidin peptide inhibitor in improved the symptoms of COVID-19 in diabetics: anti-inflammatory and potential therapeutic effects. <i>Journal of Diabetes and Metabolic Disorders</i> , 0, , .	0.8	5
1075	Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	3
1076	Evaluation of a Functional Single Nucleotide Polymorphism of the SARS-CoV-2 Receptor ACE2 That Is Potentially Involved in Long COVID. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
1077	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. <i>Nature Biomedical Engineering</i> , 2022, 6, 791-805.	11.6	100
1079	A systemic review on liquid crystals, nanoformulations and its application for detection and treatment of SARS – CoV- 2 (COVID – 19). <i>Journal of Molecular Liquids</i> , 2022, 362, 119795.	2.3	4
1080	A comparison of conventional and advanced electroanalytical methods to detect SARS-CoV-2 virus: A concise review. <i>Chemosphere</i> , 2022, 307, 135645.	4.2	3

#	ARTICLE	IF	CITATIONS
1081	Placental vascular remodeling in pregnant women with COVID-19. PLoS ONE, 2022, 17, e0268591.	1.1	7
1082	Molecular adaptations during viral epidemics. EMBO Reports, 2022, 23, .	2.0	18
1084	SARS-CoV-2 triggers pericyte-mediated cerebral capillary constriction. Brain, 2023, 146, 727-738.	3.7	16
1085	Sequence Similarity Network Analysis Provides Insight into the Temporal and Geographical Distribution of Mutations in SARS-CoV-2 Spike Protein. Viruses, 2022, 14, 1672.	1.5	0
1086	A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Journal of Virology, 2022, 96, .	1.5	15
1087	Modal analysis of novel coronavirus (SARS COV-2) using finite element methodology. Journal of the Mechanical Behavior of Biomedical Materials, 2022, 135, 105406.	1.5	4
1088	Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models. PLoS ONE, 2022, 17, e0269823.	1.1	5
1089	Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology. Biomedicines, 2022, 10, 2026.	1.4	16
1090	Analysis of medicinal and therapeutic potential of <i>Withania somnifera</i> derivatives against COVID-19. Journal of Biomolecular Structure and Dynamics, 0, , 1-11.	2.0	0
1091	Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends in Molecular Medicine, 2022, 28, 1082-1099.	3.5	11
1092	Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern. Viruses, 2022, 14, 1865.	1.5	1
1093	Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells. Biomolecules, 2022, 12, 1170.	1.8	2
1094	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	1.8	47
1095	Honey as an Adjuvant in the Treatment of COVID-19 Infection: A Review. Applied Sciences (Switzerland), 2022, 12, 7800.	1.3	6
1096	Computational Design of Mini-protein Inhibitors Targeting SARS-CoV-2 Spike Protein. Langmuir, 0, , .	1.6	6
1097	Identification of three conserved linear B cell epitopes on the SARS-CoV-2 spike protein. Emerging Microbes and Infections, 2022, 11, 2120-2131.	3.0	4
1098	Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development. Frontiers in Pharmacology, 0, 13, .	1.6	9
1099	A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. F1000Research, 0, 11, 909.	0.8	0

#	ARTICLE	IF	CITATIONS
1100	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination. <i>Nature Nanotechnology</i> , 2022, 17, 993-1003.	15.6	58
1101	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
1102	Point mutation consideration in CcO protein of the electron transfer chain by MD simulation. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 117, 108309.	1.3	5
1103	Novel Insights into Understanding the Molecular Dialogues between Bipolaroxin and the G α and G β Subunits of the Wheat Heterotrimeric G-Protein during Host-Pathogen Interaction. <i>Antioxidants</i> , 2022, 11, 1754.	2.2	1
1104	Oral inhalation of cannabidiol delivered from a metered dose inhaler to alleviate cytokine production induced by SARS-CoV-2 and pollutants. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103805.	1.4	2
1105	Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. <i>Chemico-Biological Interactions</i> , 2022, 367, 110179.	1.7	2
1106	ZnO-chlorogenic acid nanostructured complex inhibits Covid-19 pathogenesis and increases hydroxychloroquine efficacy. <i>Journal of King Saud University - Science</i> , 2022, 34, 102296.	1.6	2
1107	Paper-based sensors for rapid important biomarkers detection. <i>Biosensors and Bioelectronics: X</i> , 2022, 12, 100246.	0.9	15
1108	Insights into the Structure, Replication, and Pathogenesis of the Severe Acute Respiratory Syndrome Coronavirus 2. <i>Re:GEN Open</i> , 2022, 2, 85-92.	0.7	0
1109	Isolated specific IgA against respiratory viruses, Influenza or SARS-CoV-2, present in the saliva of a fraction of healthy and asymptomatic volunteers. <i>Clinics</i> , 2022, 77, 100105.	0.6	3
1110	Computationally Repurposed Natural Products Targeting SARS-CoV-2 Attachment and Entry Mechanisms. , 2022, , 505-537.		3
1111	SARS-CoV-2 Invasion and Pathogenesis of COVID-19: A Perspective of Viral Receptors, Bradykinin, and Purinergic System. , 2022, , 31-48.		0
1112	SARS-CoV-2 and extracellular vesicles: An intricate interplay in pathogenesis, diagnosis and treatment. <i>Frontiers in Nanotechnology</i> , 0, 4, .	2.4	3
1113	Simultaneous measurement of the antibody responses against SARS-CoV-2 and its multiple variants by a phage display mediated immuno-multiplex quantitative PCR-based assay. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
1114	Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in <i>Escherichia coli</i> for the Development of Neutralizing Antibody Assay. <i>Molecular Biotechnology</i> , 0, , .	1.3	2
1115	Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1116	In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease. <i>Molecules</i> , 2022, 27, 6374.	1.7	8
1117	Lymphocyte count is a universal predictor of health outcomes in COVID-19 patients before mass vaccination: A meta-analytical study. <i>Journal of Global Health</i> , 0, 12, .	1.2	3

#	ARTICLE	IF	CITATIONS
1119	Probing Mechanisms of Binding and Allostery in the SARS-CoV-2 Spike Omicron Variant Complexes with the Host Receptor: Revealing Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Communication with Allosteric Pockets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11542.	1.8	15
1120	Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11247.	1.8	7
1121	Towards the development of an epitope-focused vaccine for SARS-CoV-2. <i>Vaccine</i> , 2022, 40, 6489-6498.	1.7	3
1122	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
1123	A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	3
1124	A Putative long-range RNA-RNA interaction between ORF8 and Spike of SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0260331.	1.1	5
1125	Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 45, 102595.	1.7	2
1126	A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoVax in adults. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	3
1127	Effect of Recombinant Antibodies and MIP Nanoparticles on the Electrical Behavior of Impedimetric Biorecognition Surfaces for SARS-CoV-2 Spike Glycoprotein: A Short Report. <i>Electrochem</i> , 2022, 3, 538-548.	1.7	3
1128	Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10091.	1.8	8
1129	A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 661-670.	3.6	4
1130	Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. <i>Annals of Biomedical Engineering</i> , 2022, 50, 1734-1749.	1.3	5
1131	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1132	Comparative Assessment of the Inhibitory Potential of the Herbicide Glyphosate and Its Structural Analogs on RGD-Specific Integrins Using Enzyme-Linked Immunosorbent Assays. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12425.	1.8	2
1133	SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1134	SARS-CoV-2 Variants Show a Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation, an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising Structural Protein Instability: A Minimal Number Genome-Based Approach. <i>Inflammation</i> , 2023, 46, 297-312.	1.7	12
1135	Organoid Models of Heart Diseases: Find a New Channel in Improvements of Cardiac Regenerative Medicine. <i>Current Medicinal Chemistry</i> , 2023, 30, 3726-3742.	1.2	1
1136	Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction. <i>Scientific Reports</i> , 2022, 12, .	1.6	0

#	ARTICLE	IF	CITATIONS
1137	Cyclophilin A-mediated mitigation of coronavirus <sc>SARS-CoV-2</sc>. Bioengineering and Translational Medicine, 2023, 8, .	3.9	8
1138	Post-COVID-19 vaccine SARS-CoV-2 antibody investigation in healthcare professionals. The European Research Journal, 0, , 1-8.	0.1	0
1140	SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. Communications Biology, 2022, 5, .	2.0	37
1141	An Interpretable Machine Learning Approach for Hepatitis B Diagnosis. Applied Sciences (Switzerland), 2022, 12, 11127.	1.3	20
1142	Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19. Bulletin of Experimental Biology and Medicine, 2022, 173, 734-739.	0.3	4
1143	Novel Î±-aminophosphonate derivatives synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2. Journal of Molecular Structure, 2023, 1272, 134196.	1.8	25
1144	Binding Affinity Measurements Between DNA Aptamers and their Virus Targets Using ELONA and MST. Bio-protocol, 2022, 12, .	0.2	1
1146	In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2. Molecules, 2022, 27, 7572.	1.7	3
1147	2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatikam Kashayam against COVID-19: an in silico and in vitro approach. Molecular Diversity, 0, , .	2.1	0
1149	Review of Developments in Combating COVID-19 by Vaccines, Inhibitors, Radiations, and Nonthermal Plasma. Current Issues in Molecular Biology, 2022, 44, 5666-5690.	1.0	4
1150	Molecular Docking and Dynamics Simulation of Several Flavonoids Predict Cyanidin as an Effective Drug Candidate against SARS-CoV-2 Spike Protein. Advances in Pharmacological and Pharmaceutical Sciences, 2022, 2022, 1-13.	0.7	4
1151	Pooled evidence from preclinical and clinical studies for stem cell-based therapy in ARDS and COVID-19. Molecular and Cellular Biochemistry, 0, , .	1.4	2
1152	An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus. Computers in Biology and Medicine, 2023, 152, 106433.	3.9	4
1153	Polymer modification of SARS-CoV-2 spike protein impacts its ability to bind key receptor. European Polymer Journal, 2023, 184, 111767.	2.6	0
1154	A systematic review approach in understanding the COVID-19 mechanism in diabetes and its progression to diabetic microvascular complications. Journal of Diabetology, 2022, 13, 322.	0.1	0
1155	Marginal SARS-CoV-2 Spike Protein Increases Interferon and Balances Cytokine Gene Expression. International Journal of Coronaviruses, 2022, 4, 9-22.	0.8	0
1158	Structural Profiles of SARS-CoV-2 Variants in India. Current Microbiology, 2023, 80, .	1.0	4
1160	The Association between SARS-CoV-2 Infection and Diabetic Ketoacidosis in Patients with New-Onset Diabetes: A Retrospective Study from a Diabetic Center in Saudi Arabia. Pediatric Reports, 2022, 14, 519-527.	0.5	4

#	ARTICLE	IF	CITATIONS
1161	CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. <i>Viruses</i> , 2022, 14, 2665.	1.5	2
1162	End-to-End Protein Normal Mode Frequency Predictions Using Language and Graph Models and Application to Sonification. <i>ACS Nano</i> , 2022, 16, 20656-20670.	7.3	10
1164	Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. <i>Drug Delivery and Translational Research</i> , 2023, 13, 716-737.	3.0	26
1165	Investigation of Protein-Protein Interactions Utilizing a Nano-Gold Colloid Surface Plasmon Resonance: Application to SARS CoV-2 Spike Protein Coated Gold Colloids. <i>ACS Symposium Series</i> , 0, , 145-164.	0.5	0
1166	A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. <i>F1000Research</i> , 0, 11, 909.	0.8	1
1167	From acute SARS-CoV-2 infection to pulmonary hypertension. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	8
1168	Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. <i>ACS Applied Bio Materials</i> , 2023, 6, 182-190.	2.3	1
1169	Neurotropism and blood-brain barrier involvement in COVID-19. <i>Frontiers in Drug Delivery</i> , 0, 2, .	0.4	2
1170	Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	2.9	9
1171	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	42
1172	COVID-19 VACCINES: TARGETS, PRE-CLINICAL STUDIES, MECHANISMS OF ACTION, ADRS, AND ROLLOUT IN INDIA – A JOURNEY SO FAR. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 24-30.	0.3	0
1173	mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern. <i>IScience</i> , 2022, 25, 105690.	1.9	7
1174	Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment. <i>Life</i> , 2022, 12, 2117.	1.1	5
1175	Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection. <i>Structural Chemistry</i> , 2023, 34, 1743-1758.	1.0	2
1176	Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement. <i>Journal of Immunology Research</i> , 2022, 2022, 1-12.	0.9	0
1177	An Escherichia coli Expressed Multi-Disulfide Bonded SARS-CoV-2 RBD Shows Native-like Biophysical Properties and Elicits Neutralizing Antisera in a Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15744.	1.8	3
1178	Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 3274.	1.4	5
1179	Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein. <i>Journal of Virology</i> , 2022, 96, .	1.5	10

#	ARTICLE	IF	CITATIONS
1180	S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. <i>Vaccines</i> , 2023, 11, 204.	2.1	5
1181	Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1182	Infectivity of pseudotyped SARS-CoV-2 variants of concern in different human cell types and inhibitory effects of recombinant spike protein and entry-related cellular factors. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1185	Biobran/MGN-3, an Arabinoxylan Rice Bran, Protects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An In Vitro and In Silico Study. <i>Nutrients</i> , 2023, 15, 453.	1.7	7
1186	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2
1187	Effect of connection induced upper body movements on embodiment towards a limb controlled by another during virtual co-embodiment. <i>PLoS ONE</i> , 2023, 18, e0278022.	1.1	3
1188	Oxidative DNA Damage in Relation to the Severity of COVID-19 Infection in Duhok City, Kurdistan Region- Iraq. <i>Journal of Life and Bio Sciences Research</i> , 2023, 4, 01-05.	0.6	0
1189	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 37, e00780.	2.1	3
1190	Ethanol Extracts of <i>Datura innoxia</i> Have Promising Acaricidal Activity against <i>Rhipicephalus microplus</i> as It Blocks the Glutathione S-Transferase Activity of the Target Tick. <i>Genes</i> , 2023, 14, 118.	1.0	4
1191	Repurposing Mitragynine as Anti-SARS-CoV-2 Agent Evidenced by In Silico Predictive Approach. <i>Malaysian Journal of Fundamental and Applied Sciences</i> , 2022, 18, 644-653.	0.4	0
1192	Facial Nerve Palsy as Complication in COVID-19 Associated Mucormycosis: A Case Series. <i>Cureus</i> , 2022, , .	0.2	0
1193	Coagulopathy and the humoral response against viral proteins in patients at different stages of COVID-19. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	0.8	0
1194	Molecular insights into the interaction of eighteen different variants of SARS-CoV-2 spike proteins with sixteen therapeutically important phytochemicals: in silico approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 12880-12907.	2.0	0
1195	Lipid-Based Poly(I:C) Adjuvants Strongly Enhance the Immunogenicity of SARS-CoV-2 Receptor-Binding Domain Vaccine. <i>Infectious Diseases & Immunity</i> , 2023, 3, 3-12.	0.2	0
1196	From understanding bacterial interactions to developing bactericidal surfaces. , 2023, , 41-57.		0
1197	Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. <i>Pharmaceutics</i> , 2023, 15, 451.	2.0	6
1198	Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19. , 2023, , 543-568.		0
1199	Amelioration of Lead-Induced Neurotoxicity by Cucurbita pepo (Pumpkin) Fruit Extract in Wister Rats. <i>Pakistan Journal of Nutrition</i> , 2023, 22, 11-18.	0.2	0

#	ARTICLE	IF	CITATIONS
1200	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
1201	Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RABD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus. <i>Heliyon</i> , 2023, 9, e15032.	1.4	0
1202	Zebrafish-based platform for emerging bio-contaminants and virus inactivation research. <i>Science of the Total Environment</i> , 2023, 872, 162197.	3.9	4
1203	Exosomes-based particles as inhalable COVID-19 vaccines. , 2023, 4, 24-27.		3
1204	Immunological aspects of coronavirus disease caused by SARS-CoV-2. <i>Genes and Cells</i> , 2020, 15, 14-21.	0.2	5
1205	Cynomolgus Macaque Model for COVID-19 Delta Variant. <i>Immune Network</i> , 2022, 22, .	1.6	2
1206	Antibody isotype epitope mapping of SARS-CoV-2 Spike RBD protein: Targets for COVID-19 symptomatology and disease control. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	2
1207	Immunogenicity Evaluation of Thermostable Microparticles Entrapping Receptor Binding Domain of SARS-CoV-2 by Single Point Administration. <i>Journal of Pharmaceutical Sciences</i> , 2023, 112, 1664-1670.	1.6	0
1208	Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor. <i>Molecular Biotechnology</i> , 0, , .	1.3	3
1209	Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines. <i>Life</i> , 2023, 13, 474.	1.1	1
1210	Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. <i>Biomedicines</i> , 2023, 11, 517.	1.4	4
1211	Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study. <i>Lancet Microbe, The</i> , 2023, 4, e215-e227.	3.4	2
1212	RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2. <i>Viruses</i> , 2023, 15, 555.	1.5	1
1213	Investigating the competition between ACE2 natural molecular interactors and SARS-CoV-2 candidate inhibitors. <i>Chemico-Biological Interactions</i> , 2023, 374, 110380.	1.7	1
1214	Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. <i>Cells</i> , 2023, 12, 688.	1.8	21
1215	A Novel Peptide-Based Detection of SARS-CoV-2 Antibodies. <i>Biomimetics</i> , 2023, 8, 89.	1.5	2
1216	A Comprehensive Review on Potentially Therapeutic Agents against COVID-19 from Natural Sources. <i>Current Traditional Medicine</i> , 2024, 10, .	0.1	1
1217	Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals. <i>PLoS Genetics</i> , 2023, 19, e1010652.	1.5	7

#	ARTICLE	IF	CITATIONS
1218	The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2022, 9, 17-32.	0.3	1
1219	Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay. <i>Diagnostics</i> , 2023, 13, 889.	1.3	1
1220	Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents. <i>Viruses</i> , 2023, 15, 633.	1.5	3
1222	Designing and developing a sensitive and specific SARS-CoV-2 RBD IgG detection kit for identifying positive human samples. <i>Clinica Chimica Acta</i> , 2023, 542, 117279.	0.5	2
1223	Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice. <i>Viruses</i> , 2023, 15, 687.	1.5	4
1224	Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential. <i>European Journal of Medicinal Chemistry</i> , 2023, 252, 115272.	2.6	4
1225	Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions. <i>Biomedical Microdevices</i> , 2023, 25, .	1.4	7
1226	Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies. <i>Viruses</i> , 2023, 15, 741.	1.5	8
1227	Molecular Analysis of SARS-CoV-2 Spike Protein-Induced Endothelial Cell Permeability and vWF Secretion. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5664.	1.8	3
1228	Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2339-2351.	1.9	5
1230	Method for creating a recombinant strain of enterococcus L3-SARS based on biologically active strain <i>Enterococcus faecium</i> L3. , 2023, 3, 64-71.		1
1231	In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants. <i>Vaccines</i> , 2023, 11, 736.	2.1	1
1232	Intestinal Damage, Inflammation and Microbiota Alteration during COVID-19 Infection. <i>Biomedicines</i> , 2023, 11, 1014.	1.4	4
1233	Identification of an inhibitor for atherosclerotic enzyme NOX-1 to inhibit ROS production. <i>Future Journal of Pharmaceutical Sciences</i> , 2023, 9, .	1.1	1
1234	A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1235	The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling. <i>Vaccines</i> , 2023, 11, 768.	2.1	4
1236	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15207-15218.	2.0	1
1237	Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. <i>Viruses</i> , 2023, 15, 914.	1.5	5

#	ARTICLE	IF	CITATIONS
1238	Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers: Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6642.	1.8	2
1240	Deep Convolutional Neural Networks for Detecting COVID-19 Using Medical Images: A Survey. <i>New Generation Computing</i> , 2023, 41, 343-400.	2.5	3
1242	Repurposing immune boosting and anti-viral efficacy of <i>Parkia</i> bioactive entities as multi-target directed therapeutic approach for SARS-CoV-2: exploration of lead drugs by drug likeness, molecular docking and molecular dynamics simulation methods. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 43-81.	2.0	3
1243	Neurological damages in COVID-19 patients: Mechanisms and preventive interventions. <i>MedComm</i> , 2023, 4, .	3.1	4
1244	Portable Surface Plasmon Resonance Detector for COVID-19 Infection. <i>Sensors</i> , 2023, 23, 3946.	2.1	3
1245	Reinventing Therapeutic Proteins: Mining a Treasure of New Therapies. <i>Biologics</i> , 2023, 3, 72-94.	2.3	2
1246	Understanding the molecular mechanisms of statin pleiotropic effects. <i>Archives of Toxicology</i> , 2023, 97, 1529-1545.	1.9	9
1258	Use of Metallic Nanostructures in Electrochemical Biosensing of SARS-CoV-2. , 2023, , 61-70.		0
1276	An analysis of S-RBD quantitative antibody levels in post-vaccination of health workers at Jemursari Islamic hospital and Menur Mental Hospital Surabaya. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1277	Covid-19: Survival and Transmission in Wastewater and Sludge. <i>Handbook of Environmental Chemistry</i> , 2023, , .	0.2	0
1304	Post COVID-19 complications and follow up biomarkers. <i>Nanoscale Advances</i> , 2023, 5, 5705-5716.	2.2	0
1311	Circular RNA vaccine in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
1360	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0